UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒Quarterly Report pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

For the quarterly period ended ~~April 30,~~October 31, 2018.

☐Transition Report pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

For the transition period from to .

Commission file number: 001-31337

CANTEL MEDICAL CORP.

(Exact name of registrant as specified in its charter)



Delaware		22-1760285
(State or other jurisdiction of		(I.R.S. employer
incorporation or organization)		identification no.)



150 Clove Road, Little Falls, New Jersey	07424	(973) 890-7220
(Address of principal executive offices)	(Zip code)	(Registrant's telephone number, including area code)

Indicate by check mark whether registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer ☒	Accelerated filer ☐	Non-accelerated filer ☐	Smaller reporting company ☐	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Number of shares of common stock outstanding as of ~~June 1,~~November 30, 2018: ~~41,709,335.~~41,721,213.

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

TABLE OF CONTENTS



		Page No.
	PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements (unaudited)	1
	Condensed Consolidated Balance Sheets (unaudited)	1
	Condensed Consolidated Statements of Income (unaudited)	2
	Condensed Consolidated Statements of Comprehensive Income (unaudited)	3
	Condensed Consolidated Statements of Cash Flows (unaudited)	4
	Notes to Condensed Consolidated Financial Statements (unaudited)	5
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2926
Item 4.	Controls and Procedures	2926
	PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	3026
Item 1A.	Risk Factors	3026
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3026
Item 3.	Defaults Upon Senior Securities	3027
Item 4.	Mine Safety Disclosures	3027
Item 5.	Other Information	3027
Item 6.	Exhibits	3027
Signatures		3128

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed Consolidated Balance Sheets

(Unaudited)


	April 30,			July 31,
	2018			2017			October 31, 2018			July 31, 2018
Assets
Current assets:
Cash and cash equivalents	$	51,916		$	36,584		$	64,030		$	94,097
Accounts receivable, net of allowance for doubtful accounts of $1,505 and $1,808	114,146			110,656
Accounts receivable, net of allowance for doubtful accounts of $1,378 and $1,149							125,140			118,642
Inventories, net	113,109			98,724			111,071			107,592
Prepaid expenses and other current assets	17,097			11,407			17,340			17,912
Income taxes receivable	4,184			—
Total current assets	300,452			257,371			317,581			338,243

Property and equipment, net	100,759			88,338			148,584			111,417
Intangible assets, net	145,552			124,512			137,758			137,361
Goodwill	366,804			311,445			370,878			368,027
Other assets	8,404			4,707			5,512			5,749
Deferred income taxes							3,286			2,911
Total assets	$	921,971		$	786,373		$	983,599		$	963,708

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	36,628		$	27,469		$	41,984		$	34,258
Compensation payable	28,586			27,468			23,875			30,595
Accrued expenses	27,930			23,393			31,274			28,525
Deferred revenue	30,183			25,282			29,280			28,614
Current portion of long-term debt							10,000			10,000
Income taxes payable	—			3,167			7,374			2,791
Total current liabilities	123,327			106,779			143,787			134,783

Long-term debt	169,000			126,000			184,940			187,302
Deferred income taxes	23,097			24,714			27,326			27,624
Other long-term liabilities	5,241			4,948			5,186			5,132
Total liabilities	320,665			262,441			361,239			354,841
Commitments and contingencies (Note 10)
Commitments and contingencies (Note 11)

Stockholders’ equity:
Preferred Stock, par value $1.00 per share; authorized 1,000,000 shares; none issued	$	—		$	—		$	—		$	—
Common Stock, par value $0.10 per share. Authorized 75,000,000 shares; issued 46,239,890 shares and outstanding 41,709,335 shares as of April 30, 2018; issued 46,194,370 shares and outstanding 41,728,934 shares as of July 31, 2017	4,046			4,619
Common Stock, par value $0.10 per share; authorized 75,000,000 shares; issued 46,307,058 shares and outstanding 41,721,316 shares as of October 31, 2018; issued 46,243,582 shares and outstanding 41,706,084 shares as of July 31, 2018							4,631			4,624
Additional paid-in capital	183,551			174,602			187,102			184,212
Retained earnings	478,197			407,590			511,647			491,540
Accumulated other comprehensive loss	(5,292		)	(9,900		)	(16,679		)	(11,456		)
Treasury Stock, at cost; 4,530,555 shares as of April 30, 2018; 4,465,440 shares as of July 31, 2017	(59,196		)	(52,979		)
Treasury Stock, at cost; 4,585,742 shares as of October 31, 2018; 4,537,498 shares as of July 31, 2018							(64,341		)	(60,053		)
Total stockholders’ equity	601,306			523,932			622,360			608,867
Total liabilities and stockholders' equity	$	921,971		$	786,373		$	983,599		$	963,708

See accompanying notes to Condensed Consolidated Financial Statements.

(dollar amounts in thousands except share and per share data or as otherwise noted) 1

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

Condensed Consolidated Statements of Income

(Unaudited)


	Three Months Ended April 30,				Nine Months Ended April 30,					Three Months Ended October 31,
	2018		2017		2018			2017		2018		2017
Net sales
Product sales	$	189,861	$	170,073	$	564,310		$	500,878	$	195,760	$	187,965
Product service	27,407		22,040		78,758			63,777		29,829		24,801
Total net sales	217,268		192,113		643,068			564,655		225,589		212,766

Cost of sales
Product sales	93,762		84,681		283,005			250,052		99,310		95,099
Product service	18,832		15,984		53,495			45,171		21,030		17,008
Total cost of sales	112,594		100,665		336,500			295,223		120,340		112,107

Gross profit	104,674		91,448		306,568			269,432		105,249		100,659

Expenses:
Selling	33,252		30,509		95,774			85,312		33,958		31,600
General and administrative	37,784		29,204		102,068			87,672		36,535		32,096
Research and development	6,571		4,291		17,543			13,328		7,078		5,329
Total operating expenses	77,607		64,004		215,385			186,312		77,571		69,025

Income from operations	27,067		27,444		91,183			83,120		27,678		31,634

Interest expense, net	1,498		1,084		3,822			3,303		2,026		1,189
Other income	—		—		(1,138		)	—		—		(1,138		)

Income before income taxes	25,569		26,360		88,499			79,817		25,652		31,583

Income taxes	6,833		8,849		14,346			25,436		6,410		8,654

Net income	$	18,736	$	17,511	$	74,153		$	54,381	$	19,242	$	22,929

Earnings per common share:
Basic	$	0.45	$	0.42	$	1.78		$	1.30	$	0.46	$	0.55
Diluted	$	0.45	$	0.42	$	1.77		$	1.30	$	0.46	$	0.55

Dividends declared per common share	$	—	$	—	$	0.09		$	0.07
Dividends per common share										$	—	$	—

See accompanying notes to Condensed Consolidated Financial Statements.

(dollar amounts in thousands except share and per share data or as otherwise noted) 2

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)


	Three Months Ended April 30,					Nine Months Ended April 30,					Three Months Ended October 31,
	2018			2017		2018		2017			2018			2017
Net income	$	18,736		$	17,511	$	74,153	$	54,381		$	19,242		$	22,929

Other comprehensive (loss) income:
Other comprehensive loss:
Foreign currency translation	(6,538		)	1,384		4,608		(2,549		)	(5,223		)	(1,233		)
Total other comprehensive (loss) income	(6,538		)	1,384		4,608		(2,549		)
Total other comprehensive loss											(5,223		)	(1,233		)

Comprehensive income	$	12,198		$	18,895	$	78,761	$	51,832		$	14,019		$	21,696

See accompanying notes to Condensed Consolidated Financial Statements.

(dollar amounts in thousands except share and per share data or as otherwise noted) 3

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Nine Months Ended April 30,						Three Months Ended October 31,
	2018			2017			2018			2017
Cash flows from operating activities
Net income	$	74,153		$	54,381		$	19,242		$	22,929
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	12,816			10,922			4,691			4,036
Amortization	12,892			11,930			6,041			4,048
Stock-based compensation expense	7,033			6,983			2,576			1,851
Deferred income taxes	(7,499		)	(97		)	(674		)	780
Other non-cash items, net	586			519			1,236			(67		)
Changes in assets and liabilities, net of effects of business acquisitions:
Accounts receivable	892			(13,108		)	(4,087		)	8,584
Inventories	(9,791		)	(2,334		)	(3,359		)	(2,629		)
Prepaid expenses and other assets	(7,256		)	(2,924		)	1,089			(6,273		)
Accounts payable and other liabilities	13,859			9,220			1,055			(6,679		)
Income taxes	(7,682		)	(2,108		)	4,459			3,492
Net cash provided by operating activities	90,003			73,384			32,269			30,072

Cash flows from investing activities
Capital expenditures	(23,772		)	(20,765		)	(38,834		)	(6,492		)
Proceeds from disposal of fixed assets	—			43
Acquisition of businesses, net of cash acquired	(84,595		)	(69,998		)	(17,000		)	(60,345		)
Other, net	—			344
Net cash used in investing activities	(108,367		)	(90,376		)	(55,834		)	(66,837		)

Cash flows from financing activities
Repayments of long-term debt							(2,500		)	—
Borrowings under revolving credit facility	82,300			74,000			—			61,300
Repayments under revolving credit facility	(39,300		)	(45,000		)	—			(19,300		)
Dividends paid	(3,546		)	(2,921		)
Purchases of treasury stock	(6,216		)	(6,387		)	(4,288		)	(5,822		)
Net cash provided by financing activities	33,238			19,692
Net cash (used in) provided by financing activities							(6,788		)	36,178

Effect of exchange rate changes on cash and cash equivalents	458			(194		)	286			1,223

Increase in cash and cash equivalents	15,332			2,506
(Decrease) increase in cash and cash equivalents							(30,067		)	636
Cash and cash equivalents at beginning of period	36,584			28,367			94,097			36,584
Cash and cash equivalents at end of period	$	51,916		$	30,873		$	64,030		$	37,220

See accompanying notes to Condensed Consolidated Financial Statements.

(dollar amounts in thousands except share and per share data or as otherwise noted) 4

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

Notes to Condensed Consolidated Financial Statements (unaudited).

1. Basis of Presentation

Throughout this document, references to “Cantel,” “us,” “we,” “our,” and the “Company” are references to Cantel Medical Corp. and its subsidiaries, except where the context makes it clear the reference is to Cantel itself and not its subsidiaries.

During the first quarter of fiscal 2019, we changed the names of our reportable segments to better align with our key customers and the markets we serve. This decision resulted in a change from a financial reporting perspective as the industrial biological and chemical indicator business has moved from the Dental segment to the Life Sciences segment. Prior year segment disclosures have been recast to conform to the current year presentation. See Note 15, “Reportable Segments.”

Cantel is a leading provider of infection prevention products and services in the healthcare market, specializing in the following reportable segments: ~~Endoscopy, Water Purification~~Medical, Life Sciences, Dental and ~~Filtration, Healthcare Disposables and~~ Dialysis. ~~See Note 14, “Reportable Segments.”~~ Most of our equipment, consumables and supplies are used to help prevent the occurrence or spread of infections.

The unaudited Condensed Consolidated Financial Statements have been prepared in accordance with United States generally accepted accounting principles for interim financial reporting and the requirements of Form 10-Q and Rule 10.01 of Regulation S-X. Accordingly, they do not include certain information and note disclosures required by generally accepted accounting principles for annual financial reporting and should be read in conjunction with the Consolidated Financial Statements and notes thereto included in the Annual Report of Cantel Medical Corp. on Form 10-K for the fiscal year ended July 31, ~~2017~~2018 (the ~~“2017~~“2018 Form 10-K”) and Management's Discussion and Analysis of Financial Condition and Results of Operations included elsewhere herein. The unaudited interim financial statements reflect all adjustments (of a normal and recurring nature) which management considers necessary for a fair presentation of the results of operations for these periods. The results of operations for the interim periods are not necessarily indicative of the results for the full year. The Condensed Consolidated Balance Sheet at July 31, ~~2017~~2018 was derived from the audited Consolidated Balance Sheet of Cantel at that date. Certain prior year amounts have been reclassified to conform to the current year presentation.

Subsequent Events

We performed a review of events subsequent to ~~April 30,~~October 31, 2018 through the date of issuance of the accompanying unaudited consolidated interim financial statements. See Note 16, “Subsequent Event.”

2. Accounting Pronouncements

Newly Adopted Accounting Standards

In ~~September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-16, “Simplifying the Accounting for Measurement-Period Adjustments (Topic 805)”~~ (“ASU 2015-16”). The new guidance requires an acquirer in a business combination to recognize a measurement-period adjustment during the period in which it determines the amount, and eliminates the requirement for an acquirer to account for measurement-period adjustments retrospectively. The acquirer must also disclose the amounts and reasons for adjustments to the provisional amounts. ASU 2015-16 is effective for fiscal years beginning after December 15, 2016 (our fiscal year 2018), including interim periods within that reporting period. Accordingly, we adopted ASU 2015-06 on August 1, 2017. The adoption of ASU 2015-06 did not have a material impact on our financial position and results of operations.

~~In July 2015, the FASB issued ASU 2015-11,~~ ~~“Inventory (Topic 330) Simplifying the Measurement of Inventory,”~~ (“ASU 2015-11”). The new guidance requires companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016 (our fiscal year 2018), including interim periods within that reporting period. Accordingly, we adopted ASU 2015-11 on August 1, 2017. The adoption of ASU 2015-11 did not have a material impact on our financial position and results of operations.

~~In January 2017, the FASB issued ASU 2017-01, “Business Combinations (Topic 805)”~~ (“ASU 2017-01”) to clarify the definition of a business. The revised guidance creates a more robust framework to use in determining whether a set of assets and activities is a business. The guidance will be applied on a prospective basis on or after the effective date. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017 (our fiscal year 2019), including interim periods within that reporting period. We early adopted ASU-2017-01 on August 1, 2017. The adoption of ASU 2017-01 did not have a material impact on our financial position and results of operations.

~~Recently Issued Accounting Standards~~

~~In February 2018, the FASB issued ASU 2018-02,“Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”~~ (“ASU 2018-02”) to allow for the reclassification from accumulated other comprehensive income to retained earnings of stranded tax effects resulting from the Tax Cuts and Jobs Act enacted in December 2017. ASU 2018-02 is effective for fiscal

~~(dollar amounts in thousands except share and per share data or as otherwise noted) 5~~

~~Cantel Medical Corp. 2018 Third Quarter Form 10-Q~~

years beginning after December 15, 2018 (our fiscal year 2020), including interim periods within that reporting period. The adoption of ASU 2018-02 is not expected to have a significant impact on our financial position and results of operations.

~~In August 2017, the FASB issued ASU 2017-12,~~ ~~“Targeted Improvements to Accounting for Hedging Activities”~~ (“ASU 2017-12”) to improve the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. ASU 2017-12 is effective for fiscal years beginning after December 15, 2018 (our fiscal year 2020), including interim periods within that reporting period. We are currently in the process of evaluating the impact of ASU 2017-12 on our financial position and results of operations.

In May 2017, the FASB issued ASU 2017-09, ““(Topic 718) Scope of Modification ~~Accounting”~~Accounting,” (“ASU 2017-09”) to provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ~~Topic~~ASC 718. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017 (our fiscal year 2019), including interim periods within that reporting period. ~~We are currently in the process of evaluating the impact~~Accordingly, we adopted ASU 2017-09 on August 1, 2018. The adoption of ASU 2017-09 did not have a material impact on our financial position, ~~and~~ results of ~~operations.~~operations and cash flows.

In ~~January 2017,~~August 2016, the FASB issued ASU ~~2017-04,~~2016-15, “~~Intangibles - Goodwill~~(Topic 230) Classification of Certain Cash Receipts and ~~Other”~~Cash Payments,” (“ASU ~~2017-04”~~2016-15”). This guidance makes eight targeted changes to ~~simplify~~how cash receipts and cash payments are presented and classified in the ~~test for goodwill impairment. The revised guidance eliminates the existing Step 2~~statement of the goodwill impairment test which required an entity to compute the implied fair value of its goodwill at the testing date in order to measure the amount of the impairment charge when the fair value of the reporting unit failed Step 1 of the goodwill impairment test. Under the revised guidance, an entity would recognize an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value; however, the loss recognized would not exceed the total amount of goodwill allocated to the reporting unit. The guidance will be applied on a prospective basis on or after the effective date.cash flows. ASU ~~2017-04~~2016-15 is effective for fiscal years beginning after December 15, ~~2019~~2017 (our fiscal year ~~2021) and early adoption is permitted for interim or annual goodwill impairment tests performed~~2019). Accordingly, we adopted ASU 2016-15 on ~~testing dates after January~~August 1, ~~2017.~~2018. The adoption of ASU ~~2017-04 is~~2016-15 did not ~~expected to~~ have a ~~significant~~material impact on our financial position, ~~and~~ results of ~~operations.~~

~~In February 2016, FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The new guidance requires the recording of assets~~operations and liabilities arising from leases on the balance sheet accompanied by enhanced qualitative and quantitative disclosures in the notes to the financial statements. The new guidance is expected to provide transparency of information and comparability among organizations. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 (our fiscal year 2020), including interim periods within that reporting period. Early adoption is permitted as of the beginning of an interim or annual period. We are currently in the process of evaluating the impact of ASU 2016-02 on our financial position and results of operations.cash flows.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606),” (“ASU 2014-09”), which ~~will supersede~~supersedes the revenue recognition requirements in Accounting Standards Codification 605, “Revenue Recognition” (“ASC 605”). ASU 2014-09 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606),”(“ASU 2015-14”), which defers the effective date of ASU 2014-09 by one year to fiscal years beginning after December 15, 2017 (our fiscal year 2019), including interim periods within that reporting period. In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606),” (“ASU 2016-12”), which provided narrow scope improvements and practical expedients relating to ASU 2014-09. We adopted the collective standard (“ASC 606”) on August 1, 2018. See Note 5, “Revenue Recognition” for a discussion of the impact and required disclosures.

(dollar amounts in thousands except share and per share data or as otherwise noted) 5

Cantel Medical Corp. 2019 First Quarter Form 10-Q

Recently Issued Accounting Standards

In ~~preparation~~August 2018, the FASB issued ASU 2018-15,“Customer’s Accounting for ~~our~~Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (“ASU 2018-15”) to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 (our fiscal year 2021), including interim periods within that reporting period. The adoption of ASU ~~2014-09~~2018-15 is not expected to have a material impact on our financial position, results of operations or cash flows.

In August 2018, the FASB issued ASU 2018-13,“Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”) to modify the disclosure requirements on fair value measurements in ASC 820, “Fair Value Measurement”. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 (our fiscal year 2021), including interim periods within that reporting period. The adoption of ASU 2018-13 is not expected to have a material impact on our financial position, results of operations or cash flows.

In February 2018, the FASB issued ASU 2018-02,“Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income” (“ASU 2018-02”) to allow for the reclassification from accumulated other comprehensive income to retained earnings of stranded tax effects resulting from the Tax Cuts and Jobs Act enacted in December 2017. ASU 2018-02 is effective for fiscal years beginning after December 15, 2018 (our fiscal year 2020), including interim periods within that reporting period. The adoption of ASU 2018-02 is not expected to have a material impact on our financial position, results of operations or cash flows.

In August 2017, the FASB issued ASU 2017-12, “Targeted Improvements to Accounting for Hedging Activities” (“ASU 2017-12”) to improve the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. ASU 2017-12 is effective for fiscal years beginning after December 15, 2018 (our fiscal year 2020), including interim periods within that reporting period. The adoption of ASU 2017-12 is not expected to have a material impact on our financial position, results of operations or cash flows.

In January 2017, the FASB issued ASU 2017-04, “(Topic 350) Simplifying the Test for Goodwill Impairment,” (“ASU 2017-04”) to simplify the test for goodwill impairment. The revised guidance eliminates the existing Step 2 of the goodwill impairment test which required an entity to compute the implied fair value of its goodwill at the testing date in order to measure the amount of the impairment charge when the fair value of the reporting unit failed Step 1 of the goodwill impairment test. The guidance will be applied on a prospective basis on or after the effective date. ASU 2017-04 is effective for fiscal years beginning after December 31, 2019 (our fiscal year 2021) and early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of ASU 2017-04 is not expected to have a material impact on our financial position, results of operations or cash flows.

In February 2016, the FASB issued ASU 2016-02, “(Topic 842) Leases,” (“ASU 2016-02”). The new guidance requires the recording of assets and liabilities arising from leases on the balance sheet accompanied by enhanced qualitative and quantitative disclosures in the notes to the financial statements. ASU 2016-02 is effective for fiscal years beginning after December 31, 2018 (our fiscal year 2020), including interim periods within that reporting period. Early adoption is permitted as of the beginning of an interim or annual period. In July 2018, the FASB issued ASU 2018-10, “Codification Improvements to Topic 842, Leases” (“ASU 2018-10”), and ASU ~~2016-12 on August 1, 2018, we have obtained representative samples~~2018-11, “Leases (Topic 842) Targeted Improvements” (“ASU 2018-11”), which provide narrow adjustments relating to ASU 2016-02 and improvements to comparative reporting requirements for initial adoption and for separating components of ~~contracts and other forms of agreements with our customers~~a contract for lessors. We are currently in the ~~United States and in our international locations and continue to evaluate the provisions contained therein in light~~process of ~~the five-step model specified by the new guidance. We continue to evaluate~~evaluating the impact of the ~~new~~collective standard (“ASC 842”) on ~~certain common practices currently employed by us~~our financial position, results of operations and by other health care manufacturers and service providers, such as multiple-element arrangements, deferred revenues, warranties, rebates and other pricing allowances. We anticipate adopting the standard using the modified retrospective method. There may be differences in timing of revenue recognition under the new standard compared to recognition under ASC 605.cash flows.


3.	Acquisitions

Fiscal ~~2018~~2019

~~Aexis Medical~~

CES business: On ~~March 21,~~August 1, 2018, we ~~purchased all~~acquired certain net assets of ~~the issued~~Stericycle Inc. related to its controlled environmental solutions business (“CES business”) for total cash consideration, excluding acquisition-related costs, of $17,000. The CES business is a leading provider of testing and ~~outstanding stock of Aexis Medical BVBA ("Aexis Medical"). Aexis Medical specializes~~certification, environmental monitoring and decontamination services for clean rooms and other controlled environments to ensure safety, regulatory compliance and quality control, and is included in ~~advanced software solutions focused on the tracking and monitoring of instrument reprocessing for hospitals~~our Life Sciences segment.

(dollar amounts in thousands except share and per share data or as otherwise noted) 6

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

Fiscal 2018

Aexis: On March 21, 2018, we purchased all of the issued and ~~healthcare professionals. The~~outstanding stock of Aexis Medical BVBA (“Aexis”) for total consideration, ~~was $22,158,~~excluding acquisition-related costs, of $21,600, consisting of $20,308 ~~up-front~~of cash consideration (net of cash acquired), plus contingent consideration ranging from zero to a maximum of $1,850, which is payable upon the achievement of certain purchase order targets through March 21, 2020. Aexis ~~Medical~~specializes in advanced software solutions focused on the tracking and monitoring of instrument reprocessing for hospitals and healthcare professionals, and is included in our ~~Endoscopy~~Medical segment.

BHT ~~Group~~

Group: On August 23, 2017, we purchased all of the issued and outstanding stock of BHT Hygienetechnik Holding GmbH (“BHT Group”), a leader in the German market in automated endoscope reprocessing and related equipment and services for total consideration (net of cash acquired), excluding acquisition related costs, of ~~$60,787. The~~$60,216. BHT Group consists of a portfolio of high-quality automatic endoscope reprocessors, advanced endoscope storage and drying cabinets (products globally distributed by our Company prior to the acquisition under an agreement with BHT Group), washer-disinfectors for central sterile applications, associated technical service and parts as well as flexible endoscope repair services. BHT Group is included in our ~~Endoscopy~~Medical segment.

Purchase price allocations for Aexis Medical and BHT Group were based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. We anticipate completing the purchase price allocation of the BHT Group during the fourth quarter of fiscal 2018.

~~Fiscal 2017~~

~~CR Kennedy~~

On April 1, 2017, we purchased certain endoscopy-related net assets of CR Kennedy & Company Pty Ltd. (“CR Kennedy”) related to its distribution and sale of our Medivators endoscopy products in Australia for total consideration, excluding acquisition related costs, of $11,999. The CR Kennedy business includes a full sales and service organization and our Medivators-branded automated endoscope reprocessors, chemistries, endoscopy procedure products and other consumables in Australia, and is included in our Endoscopy segment.

~~Vantage Endoscopy Inc.’s Medivators~~^® ~~Endoscopy Business~~

On September 26, 2016, we acquired certain net assets of Vantage Endoscopy Inc. (“Vantage”) related to its distribution and sale of our Medivators endoscopy products in Canada for total consideration, excluding acquisition-related costs, of $4,044. Vantage was our exclusive distributor of Medivators capital equipment (e.g., automated endoscope reprocessors) and related consumables and accessories in Canada, and is included in our Endoscopy segment.

~~Accutron, Inc.~~

On August 1, 2016, we acquired all of the issued and outstanding stock of Accutron Inc. (“Accutron”), a Phoenix-based company, for total consideration, excluding acquisition-related costs, of $53,049. The Accutron business designs, manufactures and sells nitrous oxide conscious sedation equipment and single use nasal masks for use in dental procedures, and is included in our Healthcare Disposables segment.

~~(dollar amounts in thousands except share and per share data or as otherwise noted) 7~~

~~Cantel Medical Corp. 2018 Third Quarter Form 10-Q~~


	2018						2017						2019		2018
Purchase Price Allocation	Aexis Medical ⁽¹⁾			BHT Group⁽¹⁾			CR Kennedy		Vantage⁽¹⁾		Accutron⁽¹⁾		CES Business⁽¹⁾		Aexis⁽¹⁾			BHT Group⁽¹⁾
	(Preliminary)			(Preliminary)			(Final)		(Final)		(Final)		(Preliminary)		(Preliminary)			(Final)
Purchase Price:
Cash paid (net of cash acquired)	$	20,308		$	60,787		$	11,999	$	4,044	$	53,049
Cash paid													$	17,000	$	20,308		$	60,216
Fair value of contingent consideration	1,292			—			—		—		—		—		1,292			—
Total	$	21,600		$	60,787		$	11,999	$	4,044	$	53,049	$	17,000	$	21,600		$	60,216

Allocation:
Property and equipment	130			835			—		433		1,676		548		130			835
Amortizable intangible assets:
Customer relationships	—			12,500			4,200		992		12,800		8,100		1,800			12,500
Technology	11,099			6,200			—		—		10,000		—		4,600			6,200
Brand names	—			—			—		—		2,000
Goodwill	12,425			41,357			5,894		2,299		21,989		6,129		17,092			40,934
Deferred income taxes	—			(5,881		)	—		—		112		—		(1,639		)	(5,881		)
Other working capital, net	(762		)	5,776			1,905		320		4,472
Other working capital													2,223		909			5,628
Contingent consideration	(1,292		)	—			—		—		—		—		(1,292		)	—
Total	$	21,600		$	60,787		$	11,999	$	4,044	$	53,049	$	17,000	$	21,600		$	60,216


(1)	The excess purchase price over net assets acquired was assigned to goodwill, all of which is deductible for income tax purposes.

Unaudited Pro Forma Summary of Operations

The acquisitions above, both individually and in the aggregate, were not material to our consolidated results of operations or financial position and, therefore, pro forma financial information is not presented.

4. Stock-Based Compensation

2016 Equity Incentive Plan

At ~~April 30,~~October 31, 2018, ~~191,708~~281,708 nonvested restricted stock awards were outstanding under the 2016 plan. No options were outstanding under the 2016 plan. At ~~April 30,~~October 31, 2018, ~~972,312~~813,905 shares ~~are~~were collectively available pursuant to restricted stock and other stock awards, stock options and stock appreciation rights.

(dollar amounts in thousands except share and per share data or as otherwise noted) 7

Cantel Medical Corp. 2019 First Quarter Form 10-Q

2006 Equity Incentive Plan

The 2006 Plan was terminated on January 7, 2016 in conjunction with the adoption of the 2016 Plan. At ~~April 30,~~October 31, 2018, options to purchase ~~70,000~~40,000 shares of common stock were outstanding, and ~~38,295~~114 nonvested restricted stock awards were outstanding under the 2006 Plan. No additional awards will be granted under this plan.

The following table shows the components of stock-based compensation expense recognized in the condensed consolidated statements of income:



	Three Months Ended October 31,
	2018		2017
Cost of sales	$	237	$	115
Operating expenses:
Selling	571		365
General and administrative	1,710		1,333
Research and development	58		38
Total operating expenses	2,339		1,736
Stock-based compensation expense	$	2,576	$	1,851

At October 31, 2018, total unrecognized stock-based compensation expense related to total nonvested stock options and restricted stock awards was $23,664 with a remaining weighted average period of 22 months over which such expense is expected to be recognized.

We determined the fair value of our market-based restricted stock awards using a Monte Carlo simulation on the date of grant using the following assumptions:



	Three Months Ended October 31,
	2018		2017
Volatility of common stock	27.54	%	26.60	%
Average volatility of peer companies	36.55	%	33.72	%
Average correlation coefficient of peer companies	27.18	%	32.26	%
Risk-free interest rate	2.93	%	1.62	%

A summary of nonvested stock award activity for the three months ended October 31, 2018 follows:



	Number of Time-based Awards		Number of Performance-based Awards		Number of Market-based Awards	Number of Total Awards		Weighted Average Fair Value
July 31, 2018	168,320		26,076		17,710	212,106		$	88.87
Granted	117,832		27,336		16,765	161,933		$	91.91
Vested⁽¹⁾	(80,728	)	(10,235	)	—	(90,963	)	$	76.16
Forfeited	(1,254	)	—		—	(1,254	)	$	88.01
October 31, 2018	204,170		43,177		34,475	281,822		$	94.95


(1)	The aggregate fair value of all nonvested stock awards which vested was approximately $6,930.

A summary of stock option activity for the three months ended October 31, 2018 follows:



	Number of shares		Weighted Average Exercise Price		Weighted Average Contractual Life Remaining (Years)	Aggregate Intrinsic Value
Outstanding at July 31, 2018	70,000		$	38.60
Exercised	(30,000	)	31.81
Outstanding at October 31, 2018	40,000		$	43.70	1.32	$	1,418
Exercisable at October 31, 2018	40,000		$	43.70	1.32	$	1,418

(dollar amounts in thousands except share and per share data or as otherwise noted) 8

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

~~The following table shows the components of stock-based compensation expense recognized in the condensed consolidated statements of income:~~

Three Months Ended April 30, Nine Months Ended April 30,
2018 2017 2018 2017
Cost of sales $ 167
$ 83
$ 463
$ 285
Operating expenses:

Selling 559
313
1,188
1,252
General and administrative 1,641
1,520
5,231
5,358
Research and development 76
29
151
88
Total operating expenses 2,276
1,862
6,570
6,698
Stock-based compensation before income taxes $ 2,443
$ 1,945
$ 7,033
$ 6,983

At April 30, 2018, total unrecognized stock-based compensation expense, before income taxes, related to total nonvested stock options and restricted stock awards was $14,420 with a remaining weighted average period of 20 months over which such expense is expected to be recognized.

~~We determined the fair value of restricted stock awards with market conditions using a Monte Carlo simulation on the date of grant using the following assumptions:~~

2018 2017
Volatility of common stock 26.60 % 27.75 %
Average volatility of peer companies 33.72 % 32.98 %
Average correlation coefficient of peer companies 32.26 % 35.35 %
Risk-free interest rate 1.62 % 0.96 %

~~A summary of nonvested stock award activity for the nine months ended April 30, 2018 follows:~~

Number of Time-based Awards Number of Performance-based Awards Number of Market-based Awards
Number of
Total
Awards

Weighted Average
Fair Value
July 31, 2017 196,818
16,235
9,245
222,298
$ 66.28
Granted 94,130
18,647
10,465
123,242
$ 101.73
Vested⁽¹⁾
(99,009 ) (6,162 ) —
(105,171 ) $ 58.98
Forfeited (6,623 ) (1,743 ) (2,000 ) (10,366 ) $ 91.09
April 30, 2018 185,316
26,977
17,710
230,003
$ 87.55


~~(1)~~	~~The aggregate fair value of all nonvested stock awards which vested was approximately $6,203.~~

~~A summary of stock option activity for the nine months ended April 30, 2018 follows:~~

Number of shares Weighted Average Exercise Price Weighted Average Contractual Life Remaining (Years) Aggregate Intrinsic Value
Outstanding at July 31, 2017 122,500
$ 29.36

Granted —
—

Exercised (52,500 ) 17.04

Outstanding at April 30, 2018 70,000
$ 38.60
1.20 $ 5,143
Exercisable at April 30, 2018 65,000
$ 37.31
1.11 $ 4,859

During the ~~nine~~three months ended ~~April 30,~~October 31, 2018, 5,000 options vested, with an aggregate fair value of approximately ~~$132.~~$277. During the ~~nine~~three months ended ~~April 30,~~October 31, 2018, ~~52,500~~30,000 options were exercised, with an aggregate fair value of approximately ~~$4,049. As of April 30,~~$1,787. At October 31, 2018, all outstanding options were vested.

Excess tax benefits arise when the ultimate tax effect of the ~~outstanding options had vested or were expected to vest in future periods. No options were granted during~~deduction for tax purposes is greater than the ~~nine~~income tax benefit on stock-based compensation. For the three months ended ~~April 30, 2018.~~October 31, 2018, income tax deductions of $3,059 were generated, of which $2,062 were recorded as a reduction in income tax expense over the equity awards’ vesting period and the remaining excess tax benefit of $997 was recorded as a reduction in income tax expense. For the three months ended October 31, 2017, income tax deductions of $4,125 were generated, of which $1,839 were recorded as a reduction in income tax expense over the equity awards’ vesting period and the remaining excess tax benefit of $2,286 was recorded as a reduction in income tax expense.

5. Revenue Recognition

Adoption of “Revenue from Contracts with Customers (ASC 606)”

We adopted ASC 606, effective August 1, 2018, using the modified retrospective method applied to those contracts which were not completed as of August 1, 2018. Results for reporting beginning after August 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and will continue to be reported in accordance with our historic accounting under ASC 605.

Due to the cumulative impact of adopting ASC 606, we recorded a net increase to opening retained earnings, net of tax, as of August 1, 2018, which was not material. The impact is primarily related to the timing of revenue recognition for the shipment of products in both our Medical and Life Sciences segments where risk of loss provisions are present (“synthetic FOB destination”). The new standard does not require us to defer revenue for these products and allows us to recognize revenue at the time of shipment. The cumulative adjustment to retained earnings also includes the impact of the change in timing of revenue recognition associated with software licensing arrangements in our Medical segment. Additionally, revenue related to software renewals was historically recognized on a ratable basis over the license period. Under ASC 606, the license is considered functional intellectual property, and is considered to be transferred to the customer at a point in time, specifically, at the start of each annual renewal period. As a result, revenue related to our annual software license renewals has been accelerated.

Revenue Recognition

The following table gives information as to the net sales disaggregated by geography and product line:



	Three Months Ended October 31,
Net sales by geography	2018		2017⁽¹⁾
United States	$	168,938	$	160,940
Europe/Africa/Middle East	32,014		28,101
Asia/Pacific	15,752		13,607
Canada	7,373		8,476
Latin America/South America	1,512		1,642
Total	$	225,589	$	212,766
Net sales by product line
Capital equipment	$	58,132	$	59,169
Consumables	136,821		128,359
Product service	29,829		24,801
All other⁽²⁾	807		437
Total	$	225,589	$	212,766


(1)	As noted above, prior year amounts have not been adjusted under the modified retrospective method.


(2)	Primarily includes software licensing revenues.

A portion of our medical, life sciences and dialysis sales include multiple performance obligations, whereby revenue is allocated to the equipment, installation and consumable components based upon their relative standalone selling prices, which includes comparable historical transactions of similar equipment, installation and consumables sold as stand-alone components. Revenue

(dollar amounts in thousands except share and per share data or as otherwise noted) 9

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

~~Excess tax benefits arise~~on capital equipment and consumables is recognized when control of the equipment or consumable transfers to the customer, which is generally driven by the underlying shipping terms of the transaction. Revenue on the installation component is recognized when the ~~ultimate tax effect~~installation is complete. The most significant judgments related to these arrangements include (i) identifying the various performance obligations of these arrangements and (ii) determining the relative standalone selling price of each performance obligation.

With respect to certain of our customers, rebates are provided. Such rebates, which consist primarily of volume rebates, are provided for as a reduction of sales at the time of revenue recognition. Such allowances are determined based on estimated projections of sales volume for the entire rebate periods. If it becomes known that sales volume to customers will deviate from original projections, the rebate provisions originally established would be adjusted accordingly. We also offer certain volume-based rebates to our distribution customers, which we record as variable consideration when calculating the transaction price. We use information available at the time and our historical experience with each customer to estimate the rebate amount by applying the expected value method.

Remaining Performance Obligations

At October 31, 2018, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $71,549, primarily within the Medical segment. We expect to recognize revenue on approximately 70% of these remaining performance obligations over the remainder of fiscal 2019 and fiscal 2020. These performance obligations primarily reflect the future product service revenues for multi-period service arrangements.

Contract Liabilities

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Our contract liabilities arise primarily in the Medical and Life Sciences segments when payment is received upfront for various multi-period extended service arrangements. We expect to recognize substantially all of this revenue over the next twelve months. A summary of contract liabilities activity for the three months ended October 31, 2018 follows:



	Contract Liabilities
Balance, August 1, 2018	$	29,015
Revenue deferred in current year	14,524
Deferred revenue recognized	(13,547		)
Foreign currency translation	(163		)
Balance, October 31, 2018	29,829
Contract liabilities included in Other long-term liabilities	(549		)
Deferred revenue	$	29,280

Practical Expedients and Policy Elections

As part of the ~~deduction~~cost to obtain a contract, we may pay incremental commissions to sales employees upon entering into a sales contract. Under ASC 606, we have elected to expense these costs as incurred when the period of benefit is less than one year. For certain multi-period contracts, we capitalize these amounts as contract costs, and amortize them based on the contract duration to which the assets relate, which ranges from two to five years. The amounts at October 31, 2018, were not material. For certain international contracts with distributors, we recognize a receivable at the point in time in which we have an unconditional right to payment. Most customers are required to pay a portion of the transaction price in advance and the remaining balance within 30 days of receiving the related products. Accordingly, we have elected to use the practical expedient which allows us to ignore the possible existence of a significant financing component within these contracts.

As a policy, for shipping and handling costs incurred after the customer has obtained control of a good, we will continue to treat these costs as a fulfillment cost rather than as an additional promised service. Additionally, in certain U.S. states, we are required to collect sales taxes from our customers, and in certain international jurisdictions, we are required to collect value added taxes. The tax ~~purposes~~collected is greater than the income tax benefit on stock-based compensation described above. For the nine months ended April 30, 2018, income tax deductions of $3,406 were generated, of which $1,394 were previously recorded as a ~~reduction~~liability until remitted to ~~income taxes over~~ the equity awards’ vesting period and the remaining excess tax benefit of $2,012 (which includes the state income tax benefit) was recorded as a reduction to income taxes. For the nine months ended April 30, 2017, income tax deductions of $5,520 were generated, of which $3,329 were previously recorded as a reduction to income taxes over the equity awards’ vesting period and the remaining excess tax benefit of $2,191 was recorded as a reduction to income taxes.taxing authority.

(dollar amounts in thousands except share and per share data or as otherwise noted) 10

Cantel Medical Corp. 2019 First Quarter Form 10-Q

6. Inventories, Net

A summary of inventories is as follows:


	April 30, 2018			July 31, 2017			October 31, 2018			July 31, 2018
Raw materials and parts	$	49,365		$	45,831		$	53,097		$	49,054
Work-in-process	15,498			13,484			14,122			13,189
Finished goods	56,297			48,262			52,348			53,948
Reserve for excess and obsolete inventory	(8,051		)	(8,853		)	(8,496		)	(8,599		)
Total	$	113,109		$	98,724		$	111,071		$	107,592

6.7. Derivatives

In order to hedge against the impact of fluctuations in the value of the Euro, British Pound, Canadian dollar, Australian dollar and Singapore dollar relative to the U.S. dollar on the conversion of such net assets into the functional currencies, we enter into short-term forward contracts to purchase Euros, British Pounds, Canadian dollars, Australian dollars and Singapore dollars, which contracts are one-month in duration. These short-term contracts are designated as fair value hedge instruments. These foreign currency forward contracts are continually replaced with new one-month contracts as long as we have significant net assets that are denominated and ultimately settled in currencies other than each entity’s functional currency. Gains and losses related to hedging contracts to buy Euros, British Pounds, Canadian dollars, Australian dollars and Singapore dollars forward are immediately realized within general and administrative expenses due to the short-term nature of such contracts. We do not currently hedge against the impact of fluctuations in the value of the Chinese Renminbi and Sri Lankan Rupee relative to the U.S. dollar because the overall foreign currency exposure relating to these currencies is ~~currently~~ not ~~deemed significant.~~material.

There were ~~eight~~seven foreign currency forward contracts with an aggregate notional value of ~~$29,897~~$37,684 and ~~$24,762~~$30,159 at ~~April 30,~~October 31, 2018 and July 31, ~~2017,~~2018, respectively, which covered certain assets and liabilities that were denominated in currencies other than each entity’s functional currency. For the three ~~and nine~~ months ended ~~April 30,~~October 31, 2018 and 2017, the settlements of our forward contracts resulted in immaterial amounts of currency conversion gains and losses on the hedged items in the aggregate.

7.8. Fair Value Measurements

Fair Value Hierarchy

We apply the provisions of ASC 820, “Fair Value Measurements and Disclosures,” (“ASC 820”), for our financial assets and liabilities that are re-measured and reported at fair value each reporting period and our nonfinancial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis. We define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ~~ASC 820 establishes a three level fair value hierarchy to prioritize the inputs used in valuations, as defined below:~~

~~Level 1: Observable inputs that reflect unadjusted quoted prices for identical assets or liabilities in active markets.~~

~~Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.~~

~~Level 3: Unobservable inputs for the asset or liability.~~

~~(dollar amounts in thousands except share and per share data or as otherwise noted) 10~~

~~Cantel Medical Corp. 2018 Third Quarter Form 10-Q~~

Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis

Our financial assets that are re-measured at fair value on a recurring basis include money market funds that are classified as cash and cash equivalents in the consolidated balance sheets. These money market funds are classified within Level 1 of the fair value hierarchy and are valued using quoted market prices for identical assets.

For the Aexis ~~Medical~~ acquisition, additional purchase price payments ranging from zero to $1,850 are contingent upon the achievement of certain purchase order targets through March 21, 2020. We estimated the original fair value of the contingent consideration using the weighted probabilities of the possible contingent payments. ~~As of~~At the date of acquisition, we estimated the original fair value of the contingent consideration to be $1,292. We are required to reassess the fair value of contingent payments on a periodic basis. The significant inputs used in these estimates include numerous possible scenarios for the payments based on the contractual terms of the contingent consideration, for which probabilities are assigned to each scenario. Given the short term nature of the financial instrument, the contingent consideration ~~will~~is not be discounted to present value. Although we believe our assumptions are reasonable, different assumptions or changes in the future may result in different estimated amounts.

In connection with the Jet Prep Ltd. ("(“Jet ~~Prep"~~Prep”) acquisition in fiscal 2014, we assumed a contingent obligation payable to the Israeli Government based on future sales. This fair value measurement was based on significant inputs not observed in the market and thus represent Level 3 measurements. In November 2017, the Israeli Government formally notified us that they would forgive any future amounts payable due to our decision to exit the Jet Prep business. During the first quarter of fiscal 2018, we reduced the fair value of this obligation to ~~$0.~~zero. See Note ~~10,~~11, "Commitments and Contingencies."

~~The fair values of the Company’s financial instruments measured on a recurring basis were categorized as follows:~~

April 30, 2018
Level 1 Level 2 Level 3 Total
Assets:

Cash and cash equivalents:

Money markets $ 103
$ —
$ —
$ 103
Total assets $ 103
$ —
$ —
$ 103
Liabilities:

Long-term debt⁽¹⁾
—
169,000
—
169,000
Other long-term liabilities:

Contingent consideration —
—
1,262
1,262
Total other long-term liabilities: —
—
1,262
1,262
Total liabilities $ —
$ 169,000
$ 1,262
$ 170,262

~~(1) Fair value estimated using Level 2 inputs, which were quoted prices for identical or similar instruments in markets that are not active.~~

(dollar amounts in thousands except share and per share data or as otherwise noted) 11

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

July 31, 2017
Level 1 Level 2 Level 3 Total
Assets:

Cash and cash equivalents:

Money markets $ 102
$ —
$ —
$ 102
Total assets $ 102
$ —
$ —
$ 102
Liabilities:

Accrued expenses:

Assumed contingent obligation —
—
12
12
Total accrued expenses —
—
12
12
Long-term debt⁽¹⁾
—
126,000
—
126,000
Other long-term liabilities:

Assumed contingent obligation —
—
1,126
1,126
Total other long-term liabilities: —
—
1,126
1,126
Total liabilities $ —
$ 126,000
$ 1,138
$ 127,138


~~(1)~~	~~Fair value estimated using Level 2 inputs, which were quoted prices for identical or similar instruments in markets that are not active.~~

The ~~following table summarizes the Level 3 activity~~fair values of our financial ~~instruments:~~

instruments measured on a recurring basis were categorized as follows:

Three Months Ended April 30, Nine Months Ended April 30,
2018 2017 2018 2017
Beginning balance $ —
$ 1,138
$ 1,138
$ 1,138
Original fair value of contingent consideration⁽¹⁾
1,292
—
1,292
—
Foreign currency translation (30 ) —
(30 ) —
Net settlements⁽²⁾
—
—
(1,138 ) —
Ending Balance $ 1,262
$ 1,138
$ 1,262
$ 1,138



	October 31, 2018
	Level 1		Level 2		Level 3		Total
Assets:
Cash and cash equivalents:
Money markets	$	104	$	—	$	—	$	104
Total assets	$	104	$	—	$	—	$	104
Liabilities:
Other long-term liabilities:
Contingent consideration	—		—		1,320		1,320
Total liabilities	$	—	$	—	$	1,320	$	1,320


~~(1)~~	~~For the three and nine months ended April 30, 2018, the amounts represent the contingent consideration associated with the Aexis Medical acquisition.~~


~~(2)~~	~~For the nine months ended April 30, 2018, the amount represents the resolution of the Jet Prep obligation.~~



	July 31, 2018
	Level 1		Level 2		Level 3		Total
Assets:
Cash and cash equivalents:
Money markets	$	104	$	—	$	—	$	104
Total assets	$	104	$	—	$	—	$	104
Liabilities:
Other long-term liabilities:
Contingent obligation	—		—		1,298		1,298
Total liabilities	$	—	$	—	$	1,298	$	1,298

A reconciliation of our liabilities that are measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows:



	Aexis Contingent Consideration		Jet Prep Assumed Contingent Obligation		Total
Balance, July 31, 2018	$	1,298	$	—	$	1,298
Loss included in general and administrative expense	22		—		22
Net purchases, issuances, sales and settlements	—		—		—
Balance, October 31, 2018	$	1,320	$	—	$	1,320

Disclosure of Fair Value of Financial Instruments

~~As of April 30,~~At October 31, 2018 and July 31, ~~2017,~~2018, the carrying amounts for cash and cash equivalents (excluding money markets), accounts receivable and accounts payable approximated fair value due to the short maturity of these instruments. At October 31, 2018 and July 31, 2018, the carrying value of our outstanding borrowings under our credit facility approximated the fair value of these obligations as the respective borrowings rates reflect prevailing market interest rates.

(dollar amounts in thousands except share and per share data or as otherwise noted) 12

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q


8.9.	Intangibles and Goodwill

~~The Company’s~~Our intangible assets consist of the following:


	April 30, 2018							July 31, 2017							October 31, 2018							July 31, 2018
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Intangible assets with finite lives:
Customer relationships(1)	$	133,133	$	(43,145	)	$	89,988	$	119,576	$	(34,773	)	$	84,803	$	134,866	$	(43,177	)	$	91,689	$	133,347	$	(45,618	)	$	87,729
Technology⁽¹⁾	59,080		(18,663		)	40,417		39,064		(15,260		)	23,804		50,918		(18,724		)	32,194		54,585		(19,836		)	34,749
Brand names(1)	8,230		(3,719		)	4,511		8,188		(3,225		)	4,963		6,874		(2,774		)	4,100		8,141		(3,857		)	4,284
Non-compete agreements(1)	3,060		(1,571		)	1,489		3,092		(1,428		)	1,664		2,880		(1,505		)	1,375		3,060		(1,628		)	1,432
Patents and other registrations	2,767		(1,144		)	1,623		2,783		(1,053		)	1,730		2,855		(1,150		)	1,705		2,826		(1,179		)	1,647
	206,270		(68,242		)	138,028		172,703		(55,739		)	116,964		198,393		(67,330		)	131,063		201,959		(72,118		)	129,841
Trademarks and tradenames	7,524		—			7,524		7,548		—			7,548		6,695		—			6,695		7,520		—			7,520
Total intangible assets	$	213,794	$	(68,242	)	$	145,552	$	180,251	$	(55,739	)	$	124,512	$	205,088	$	(67,330	)	$	137,758	$	209,479	$	(72,118	)	$	137,361

(1)

~~The gross and accumulated amortization amounts previously reported as~~During the first quarter of ~~July 31, 2017 have been revised to exclude the $3,730~~fiscal 2019, we wrote off $10,335 of fully amortized ~~technology related~~ intangible ~~asset and associated accumulated amortization related to the Jet Prep business. This did not result in any change to the net technology related intangible asset as of July 31, 2017.~~assets.

Amortization expense related to intangible assets was ~~$4,480~~$6,041 and ~~$3,964~~$4,048 for the three months ended ~~April 30, 2018 and 2017, respectively, and $12,892 and $11,930 for the nine months ended April 30,~~October 31, 2018 and 2017, respectively. We expect to recognize an additional ~~$5,253~~$13,451 of amortization expense related to intangible assets for the remainder of fiscal ~~2018,~~2019, and thereafter ~~$18,008, $16,315, $16,313, $15,969~~$16,288, $15,949, $15,948, $15,576 and ~~$15,586~~$14,476 of amortization expense for fiscal years ~~2019,~~ 2020, 2021, 2022, 2023 and ~~2023,~~2024, respectively.

Goodwill changed during the ~~nine~~three months ended ~~April 30,~~October 31, 2018 as follows:


	Endoscopy		Water Purification and Filtration			Healthcare Disposables		Dialysis		Total Goodwill		Medical			Life Sciences			Dental		Dialysis		Total Goodwill
Balance, July 31, 2017	$	129,945	$	59,088		$	114,279	$	8,133	$	311,445
Balance, July 31, 2018												$	186,690		$	58,925		$	114,279	$	8,133	$	368,027
Acquisitions	53,782		—			—		—		53,782		—			6,129			—		—		6,129
Foreign currency translation	1,717		(140		)	—		—		1,577		(3,180		)	(98		)	—		—		(3,278		)
Balance, April 30, 2018	$	185,444	$	58,948		$	114,279	$	8,133	$	366,804
Balance, October 31, 2018												$	183,510		$	64,956		$	114,279	$	8,133	$	370,878

9.10. Financing Arrangements

~~Borrowings~~Our long-term debt consists of the following:



	October 31, 2018			July 31, 2018
Tranche A term loan outstanding	$	197,500		$	200,000
Unamortized debt issuance costs	(2,560		)	(2,698		)
Total long-term debt, net of unamortized debt issuance costs	194,940			197,302
Current portion of long-term debt	(10,000		)	(10,000		)
Long-term debt, net of unamortized debt issuance costs and excluding current portion	$	184,940		$	187,302

On June 28, 2018, we entered into a Fourth Amended and Restated Credit Agreement (the “2018 Credit Agreement”). The 2018 Agreement refinances our credit facility under ~~our~~the Third Amended and Restated Credit Agreement (the ~~“2014~~“Existing Credit Agreement”) dated March 4, 2014, to include a $200,000 tranche A term loan and a $400,000 revolving credit facility. Subject to the satisfaction of certain conditions precedent, including the consent of the lenders, we may from time to time increase our borrowing capacity under the revolving credit facility or tranche A term loan by an aggregate amount not to exceed $300,000. The 2018 Credit Agreement expires on June 28, 2023. Additionally, subject to certain restrictions and conditions (i) any of our domestic or foreign subsidiaries may become borrowers and (ii) borrowings may occur in multi-currencies.

At October 31, 2018, we had $197,500 of term loan A borrowings outstanding and no revolver borrowings under the 2018 Credit Agreement. The tranche A term loan is subject to principal amortization, with $10,000 due and payable in each of fiscal 2019,

(dollar amounts in thousands except share and per share data or as otherwise noted) 13

Cantel Medical Corp. 2019 First Quarter Form 10-Q

2020, 2021 and 2022, with the remaining $160,000 due and payable at maturity on June 28, 2023. During the three months ended October 31, 2018, we made principal payments of $2,500.

Borrowings under the 2018 Credit Agreement bear interest at rates ranging from ~~0.25%~~0.00% to ~~1.25%~~1.00% above ~~the lender’s~~prime rate for base rate borrowings, or at rates ranging from ~~1.25%~~1.00% to ~~2.25%~~2.00% above the London Interbank Offered Rate (“LIBOR”), depending upon ~~the Company’s~~our “Consolidated Leverage Ratio,” which is defined as the consolidated ratio of total funded debt to earnings before interest, taxes, depreciation and amortization, and as further adjusted under the terms of the ~~2014~~2018 Credit Agreement (“Consolidated EBITDA”). At ~~April 30,~~October 31, 2018, the lender’s base rate was ~~5.00%~~5.25% and the LIBOR ~~rates ranged from 1.89% to 1.90%~~rate was 2.30%. The margins applicable to our outstanding borrowings were 0.25% above the lender’s base rate or 1.25% above LIBOR. All of our outstanding borrowings were under LIBOR contracts at ~~April 30,~~October 31, 2018. The ~~2014~~2018 Credit Agreement also provides for fees on the unused portion of our facility at rates ranging from 0.20% to ~~0.40%~~0.35%, depending upon our Consolidated Leverage Ratio, which was 0.20% at ~~April 30,~~October 31, 2018. At October 31, 2018, the tranche A term loan interest rate was approximately 3.55%.

The ~~2014~~2018 Credit Agreement contains affirmative and negative covenants reasonably customary for similar credit facilities and is secured by (i) substantially all assets of Cantel and its U.S.-based subsidiaries, (ii) a pledge by Cantel of all of the outstanding shares of its U.S.-based subsidiaries and 65% of the outstanding shares of certain of Cantel’s foreign-based subsidiaries and (iii) a guaranty by Cantel’s domestic subsidiaries. We are in compliance with all financial ~~and other~~ covenants under the ~~2014~~2018 Credit Agreement.

As of April 30, 2018 and July 31, 2017, we had $169,000 and $126,000, respectively, of outstanding borrowings under the 2014 Credit Agreement. Debt issuance costs associated with our credit facilities are capitalized and amortized to interest expense over

~~(dollar amounts in thousands except share and per share data or as otherwise noted) 13~~

~~Cantel Medical Corp. 2018 Third Quarter Form 10-Q~~

the term of the credit facilities. As of April 30, 2018 and July 31, 2017, such debt issuance costs, net of related amortization, were included in other assets, and amounted to $334 and $580, respectively.

~~10.~~11. Commitments and Contingencies

Contingent Consideration and Assumed Contingent Liability

At October 31, 2018, $1,320 was recorded related to the Aexis acquisition, which is for the estimated fair value of contingent consideration payable upon the achievement of certain purchase order targets through March 21, 2020. During fiscal 2017, we decided to exit the Jet Prep business that was acquired in fiscal 2014. At the time of the acquisition, we assumed a contingent obligation payable to the Israeli Government based on future sales. In November 2017, the Israeli Government formally notified us that they would forgive any future amounts payable due to our decision to exit the Jet Prep business. As a result of this formal notification, we reduced the $1,138 contingent obligation to $0zero during the first quarter of fiscal 2018, resulting in a benefit through other income for the ~~nine~~three months ended ~~April 30, 2018.~~October 31, 2017.

Legal Matters

In May 2017, Cantel Medical (UK) Limited and Cantel (UK) Limited filed a lawsuit in the UK High Court of Justice against ARC Medical Design Limited (“ARC”) seeking a judgment of invalidity on two of ARC’s patents and additionally/alternatively a declaration of non-infringement of our AmplifEYE^TM ~~Endoscopic device. ARC filed counterclaims alleging that the AmplifEYE~~^TM ~~device infringed the two patents as well as registered community design marks and unregistered design rights that ARC had in its Endocuff~~^TM ~~and Endocuff Vision~~^TM devices. In February 2018, the trial judge entered a judgment in favor of ARC, and we decided not to appeal the decision. We entered into a settlement agreement with ARC in March 2018 under which we agreed not to make, use, sell or offer to sell the AmplifEYE^TMdevice in the European Union until ARC’s rights expire, and reimbursed ARC for a portion of their legal costs. During the third quarter of fiscal 2018, we recorded $2,608 of litigation costs within selling, general and administrative expenses associated with this matter.

In the normal course of business, we are subject to pending and threatened legal actions. It is our policy to accrue for amounts related to these legal matters if it is probable that a liability has been incurred and an amount of anticipated exposure can be reasonably estimated. We do not believe that any of these pending claims or legal actions will have a material effect on our business, financial condition, results of operations or cash flows.

~~11.~~12. Earnings Per Common Share

Basic EPS is computed based upon the weighted average number of common shares outstanding for the year. Diluted EPS is computed based upon the weighted average number of common shares outstanding for the year plus the dilutive effect of common stock equivalents using the treasury stock method and the average market price of our common stock for the year. We include participating securities (nonvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents) in the computation of EPS pursuant to the two-class method. Our participating securities consist solely of nonvested restricted stock awards, which have contractual participation rights equivalent to those of stockholders of unrestricted common stock. The two-class method of computing earnings per share is an allocation method that calculates earnings per share for common stock and participating securities.

(dollar amounts in thousands except share and per share data or as otherwise noted) 14

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

The following table sets forth the computation of basic and diluted EPS available to stockholders of common stock (excluding participating securities):


	Three Months Ended						Nine Months Ended
	April 30,						April 30,						Three Months Ended October 31,
	2018			2017			2018			2017			2018			2017
Numerator for basic and diluted earnings per share:
Net income	$	18,736		$	17,511		$	74,153		$	54,381		$	19,242		$	22,929
Less income allocated to participating securities	(59		)	(98		)	(281		)	(335		)	(33		)	(124		)
Net income available to common shareholders	$	18,677		$	17,413		$	73,872		$	54,046		$	19,209		$	22,805
Denominator for basic and diluted earnings per share, as adjusted for participating securities:
Denominator for basic and diluted earnings per share, adjusted for participating securities:
Denominator for basic earnings per share - weighted average number of shares outstanding attributable to common stock	41,580,387			41,489,587			41,559,312			41,459,067			41,640,745			41,521,952
Dilutive effect of stock awards using the treasury stock method and the average market price for the year	69,134			75,431			63,642			74,420			65,028			66,233
Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock	41,649,521			41,565,018			41,622,954			41,533,487			41,705,773			41,588,185
Earnings per share attributable to common stock:
Basic earnings per share	$	0.45		$	0.42		$	1.78		$	1.30		$	0.46		$	0.55
Diluted earnings per share	$	0.45		$	0.42		$	1.77		$	1.30		$	0.46		$	0.55
Stock options excluded from weighted average dilutive common shares because their inclusion would have been anti-dilutive	—			—			—			—			—			—

A reconciliation of weighted average number of shares and common stock equivalents attributable to common stock, as determined above, to ~~the Company’s~~our total weighted average number of shares and common stock equivalents, including participating securities, is set forth in the following table:


	Three Months Ended		Nine Months Ended
	April 30,		April 30,		Three Months Ended October 31,
	2018	2017	2018	2017	2018	2017
Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock	41,649,521	41,565,018	41,622,954	41,533,487	41,705,773	41,588,185
Participating securities	133,954	233,501	159,932	259,050	69,452	225,675
Total weighted average number of shares and common stock equivalents attributable to both common stock and participating securities	41,783,475	41,798,519	41,782,886	41,792,537	41,775,225	41,813,860

12.13. Income Taxes

On December 22, 2017, the U.S. government enacted wide-ranging tax legislation, the Tax Cuts and Jobs Act (the “2017 Tax Act”). The 2017 Tax Act significantly revises U.S. tax law by, among other provisions, (a) lowering the applicable U.S. federal statutory income tax rate from 35% to 21%, (b) creating a partial territorial tax system that includes imposing a mandatory one-time transition tax on previously deferred foreign earnings, (c) creating provisions regarding the (1) Global Intangible Low Tax Income (“GILTI”), (2) the Foreign Derived Intangible Income (“FDII”) deduction, and (3) the Base Erosion Anti-Abuse Tax (“BEAT”), and (d) eliminating or reducing certain income tax deductions, such as interest expense, executive compensation expenses and certain employee expenses.

ASC 740, “Income Taxes,” requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the 2017 Tax Act’s provisions, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which allows companies to record the tax effects of the 2017 Tax Act on a provisional basis based on a reasonable estimate and then, if necessary, subsequently adjust such amounts during a limited measurement period as more information becomes available. The measurement period ends when a company has obtained, prepared, and analyzed the information necessary to finalize its accounting, but cannot extend beyond one year from enactment.

~~(dollar amounts in thousands except share and per share data or as otherwise noted) 15~~

~~Cantel Medical Corp. 2018 Third Quarter Form 10-Q~~

Section 15 of the Internal Revenue Code (the “Code”) governs rate changes and was not amended by the 2017 Tax Act. Section 15 requires a blended tax rate for fiscal-year taxpayers for their fiscal year that includes the effective date of the rate change, which was January 1, 2018. As a result of the 2017 Tax Act, we revised our estimated annual effective rate to reflect the change in the U.S. federal statutory rate by computing a tentative tax under both rates, and then prorating the tentative tax based on the number of days with and without the rate change to arrive at a blended tax rate of 26.9%, as required by the ~~code.~~Code. This blended rate was

(dollar amounts in thousands except share and per share data or as otherwise noted) 15

Cantel Medical Corp. 2019 First Quarter Form 10-Q

applied for fiscal 2018 (beginning with the second quarter) and the new U.S. federal statutory rate of 21% ~~will apply~~applies to fiscal 2019 and beyond.

During the second quarter ended January 31, 2018, we recorded a net benefit of $8,398 to the income tax provision as a provisional estimate of the net accounting impact of the 2017 Tax Act in accordance with SAB 118. The net benefit is comprised of the following: (i) expense of $294 related to the mandatory transition tax for deemed repatriation of deferred foreign income and (ii) a benefit of $8,692 related to a revaluation of our deferred tax assets and liabilities. During the third quarter ended April 30, 2018, we reduced the mandatory transition tax by $294.

Given the significant complexity of the 2017 Tax Act, anticipated guidance from the U.S. Treasury concerning implementation of the 2017 Tax Act, and the potential for additional guidance from the SEC or the FASB related to the 2017 Tax Act, the provisional estimates we recorded may require adjustment during the measurement period. The provisional estimates were based on our understanding of the 2017 Tax Act and other information available at the time of the estimates, including assumptions and expectations about future events, such as projected financial performance, and are subject to further refinement as additional information becomes available, ~~(including our actual full fiscal 2018 results of operations, as well as~~including potential new or interpretative guidance issued by the SEC, the FASB, or the Internal Revenue ~~Service) and as we continue our analysis.~~Service (“IRS”). We continue to analyze the ~~changes to certain income tax deductions, assess~~ calculations of earnings and profits in certain foreign subsidiaries, including whether those earnings are held in cash or other assets, and gather additional data to compute the full impact of the 2017 Tax Act on our deferred and current tax assets and liabilities. Furthermore, such analysis includes but is not limited to provisions regarding the GILTI and certain employee expense deductions, as well as the state tax impact of the 2017 Tax Act. ~~During~~Furthermore, such analysis includes but is not limited to provisions that take effect in fiscal 2019 and not subject to SAB 118 such as GILTI and certain employee expense deductions. In the ~~third~~fourth quarter ended ~~April 30,~~July 31, 2018, we ~~reduced~~recorded a benefit of $8,657 due to the mandatory transition tax by $294. We are currently in the process of further analyzing its structure and estimated future results and, as a result, are not yet able to reasonably estimate the effect of these provisionsimpact of the 2017 Tax ~~Act.~~Act on our deferred tax assets and liabilities on the basis of actual fiscal 2018 results of operations.

A reconciliation of the consolidated effective income tax rate from the three ~~and nine~~ months ended ~~April 30,~~October 31, 2017 to the three ~~and nine~~ months ended ~~April 30,~~October 31, 2018 is as follows:

Consolidated Effective
Income Tax Rate
Three Months Ended Nine Months Ended
April 30, 2017 33.6 % 31.9 %
Difference attributable to:
Deferred tax revaluation (0.4 )% (7.0 )%
U.S. federal statutory rate decrease⁽¹⁾
(8.1 )% (8.1 )%
Foreign operations (1.3 )% (0.3 )%
State taxes 3.5 % 1.5 %
Excess tax benefit — % (2.3 )%
Other (0.6 )% 0.5 %
April 30, 2018 26.7 % 16.2 %



~~(1)~~Effective Rate, October 31, 2017	~~The Company revised its estimated annual rate to reflect a blended~~ 27.4	%
U.S. federal statutory rate ~~of 26.9% as compared to 35.0%.~~decrease	(14.0	)%
Foreign operations	5.0	%
State taxes	0.9	%
Excess tax benefit	3.4	%
Other	2.3	%
Effective Rate, October 31, 2018	25.0	%

~~(dollar amounts in thousands except share and per share data or as otherwise noted) 16~~

~~Cantel Medical Corp. 2018 Third Quarter Form 10-Q~~

~~13.~~14. Accumulated Other Comprehensive ~~(Loss) Income~~Loss

The components and changes in accumulated other comprehensive ~~(loss) income~~loss were as follows:


	Three Months Ended April 30,						Nine Months Ended April 30,						Three Months Ended October 31,
	2018			2017			2018			2017			2018			2017
Beginning balance	$	1,246		$	(15,728	)	$	(9,900	)	$	(11,795	)	$	(11,456	)	$	(9,900	)
Other comprehensive (loss) income for foreign currency translation	(6,538		)	1,384			4,608			(2,549		)
Other comprehensive loss for foreign currency translation													(5,223		)	(1,233		)
Ending balance	$	(5,292	)	$	(14,344	)	$	(5,292	)	$	(14,344	)	$	(16,679	)	$	(11,133	)

~~14.~~15. Reportable Segments

In accordance with ~~FASB~~ ASC Topic 280, “Segment Reporting,” (“ASC 280”), we have determined our reportable business segments based upon an assessment of product types, organizational structure, customers and internally prepared financial statements. The primary factors used by us in analyzing segment performance are net sales and ~~operating income.~~income from operations.

~~The Company’s~~

During the first quarter of fiscal 2019, we changed the names of our reportable segments to better align with our key customers and the markets we serve. As a result of this change, our industrial biological and chemical indicator business has moved from the Dental segment to the Life Sciences segment. Prior year segment disclosures have been recast to conform to the current year presentation.

Our reportable segments are as follows:

~~Endoscopy:~~Medical: designs, develops, manufactures, sells and installs a comprehensive offering of products and services comprising a complete circle of infection prevention solutions. Our products include endoscope reprocessing and endoscopy procedure products.

~~Water Purification and Filtration:~~Life Sciences: designs, develops, manufactures, sells, and installs water purification systems for medical, pharmaceutical and other bacteria controlled applications. We also provide filtration/separation and disinfectant technologies to the medical and life science markets through a worldwide distributor network. Two customers collectively accounted for approximately ~~50.1%~~43.9% and ~~50.7%~~53.4% of our ~~Water Purification and Filtration~~Life Sciences segment net sales for the ~~nine~~three months ended ~~April 30,~~October 31, 2018 and 2017, respectively.

(dollar amounts in thousands except share and per share data or as otherwise noted) 16

Cantel Medical Corp. 2019 First Quarter Form 10-Q

~~Healthcare Disposables:~~Dental: designs, manufactures, sells, supplies and distributes a broad selection of infection prevention healthcare products, the majority of which are single-use products used by dental practitioners. Three customers collectively accounted for approximately ~~47.7%~~50.2% and ~~50.4%~~49.1% of our ~~Healthcare Disposables~~Dental segment net sales for the ~~nine~~three months ended ~~April 30,~~October 31, 2018 and 2017, respectively.

Dialysis: designs, develops, manufactures, sells and services reprocessing systems and sterilants for dialyzers (a device serving as an artificial kidney), as well as dialysate concentrates and supplies utilized for renal dialysis. Two customers accounted for approximately ~~39.0%~~41.4% and ~~38.8%~~43.1% of our Dialysis segment net sales for the ~~nine~~three months ended ~~April 30,~~October 31, 2018 and 2017, respectively. These customers are the same two customers noted above under our Life Sciences segment.

~~Information as to reportable segments is summarized below:~~

Three Months Ended April 30, Nine Months Ended April 30,
2018 2017 2018 2017
Net sales:

Endoscopy $ 118,396
$ 100,349
$ 347,446
$ 288,544
Water Purification and Filtration 52,330
47,940
156,828
145,233
Healthcare Disposables 38,522
36,177
114,898
108,256
Dialysis 8,020
7,647
23,896
22,622
Total $ 217,268
$ 192,113
$ 643,068
$ 564,655

None of our customers accounted for 10% or more of our consolidated net sales for the ~~nine~~three months ended ~~April 30,~~October 31, 2018 and 2017.

Information as to reportable segments is summarized below:



	Three Months Ended October 31,
Net sales	2018		2017
Medical	$	127,552	$	112,385
Life Sciences	53,345		54,770
Dental	36,628		37,677
Dialysis	8,064		7,934
Total net sales	$	225,589	$	212,766



	Three Months Ended October 31,
Income from operations	2018		2017
Medical	$	25,211	$	19,684
Life Sciences	6,331		10,375
Dental	5,925		8,675
Dialysis	1,384		2,099
	38,851		40,833
General corporate expenses	11,173		9,199
Total income from operations	$	27,678	$	31,634

16. Subsequent Event

(dollar amounts in thousands except share and per share data or as otherwise noted) 17

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

Three Months Ended April 30, Nine Months Ended April 30,
2018 2017 2018 2017
Segment operating income:

Endoscopy $ 20,515
$ 18,514
$ 64,662
$ 54,853
Water Purification and Filtration 8,454
7,842
26,753
25,167
Healthcare Disposables 7,588
6,392
23,481
20,857
Dialysis 1,778
2,315
5,795
6,275
38,335
35,063
120,691
107,152
General corporate expenses⁽¹⁾
11,268
7,619
29,508
24,032
Operating income $ 27,067
$ 27,444
$ 91,183
$ 83,120

~~_______________________________________________~~


~~(1)~~	General corporate expenses relate to unallocated corporate costs primarily related to executive management personnel as well as costs associated with certain facets of our acquisition program and being a publicly traded company.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help you understand ~~Cantel Medical Corp. (“Cantel”).~~Cantel. The MD&A is provided as a supplement to and should be read in conjunction with our financial statements and the accompanying notes.

Overview

Cantel is a leading provider of infection prevention products and services in the healthcare market, specializing in the following reportable segments: ~~Endoscopy, Water Purification and Filtration, Healthcare Disposables~~Medical, Life Sciences, Dental and Dialysis. Most of our equipment, consumables and supplies are used to help prevent the occurrence or spread of infections.

~~Third~~

First Quarter ~~2018~~2019 Highlights

Some of our key financial results for the three months ended ~~April 30,~~October 31, 2018 compared with the three months ended ~~April 30,~~October 31, 2017 were as follows:

Net sales increased by ~~13.1%~~6.0% to ~~$217,268~~$225,589 from ~~$192,113,~~$212,766, with organic net sales growth of ~~7.6%~~4.3%

Net income ~~increased~~decreased by ~~7.0%~~16.1% to ~~$18,736~~$19,242 from ~~$17,511~~$22,929

Non-GAAP net income increased by ~~16.6%~~7.7% to ~~$24,929~~$25,891 from ~~$21,377~~$24,041

Diluted EPS ~~increased~~decreased by ~~7.0%~~16.0% to ~~$0.45~~$0.46 from ~~$0.42~~$0.55

Non-GAAP diluted EPS increased by ~~16.6%~~7.9% to ~~$0.60~~$0.62 from ~~$0.51~~$0.57

Adjusted EBITDAS increased by ~~12.3%~~0.8% to ~~$43,569~~$44,771 from ~~$38,813~~$44,395

See Non-GAAP Financial Measures below.

~~U.S. Tax Reform~~Reportable Segment Name Changes

~~The 2017 Tax Act, among other provisions, lowered~~During the ~~applicable U.S. federal statutory income tax rate~~first quarter of fiscal 2019, we changed the names of our reportable segments to better align with our key customers and the markets we serve. As a result of this change, our industrial biological and chemical indicator business has moved from ~~35%~~the Dental segment to ~~21%~~the Life Sciences segment. Prior year segment disclosures have been recast to conform to the current year presentation.

Acquisitions

On November 12, 2018, we entered into a definitive agreement to purchase Omnia S.p.A. (“Omnia”), an Italian-based market leader in dental surgical consumables solutions, for total consideration, excluding acquisition-related costs, of $31,900, consisting of $26,100 of cash and ~~implemented~~stock consideration (net of cash acquired), plus contingent consideration ranging from zero to a maximum of $5,800, which is payable upon the ~~imposition~~achievement of certain performance-based targets. Omnia’s business consists of a ~~one-time transition tax~~wide-ranging portfolio of sutures, irrigation tubing and customized dental surgical procedure kits, with a focus on ~~previously deferred foreign earnings. ASC 740 requires the effects of changes~~procedure room set-up and cross-contamination prevention. Omnia will be included in ~~tax laws to be recognized in the period in which the legislation is enacted, including the revaluation of deferred income tax assets and liabilities. During the second quarter ended January 31,~~our Dental segment.

On August 1, 2018, we ~~recorded a~~acquired certain net ~~benefit~~assets of $8,398 to the income tax provision as a provisional estimate of the net accounting impact of the 2017 Tax Act in accordance with SAB 118. The net benefit is comprised of the following: (i) expense of $294Stericycle Inc. related to ~~the mandatory transition tax~~its controlled environmental solutions business (“CES business”) for ~~deemed repatriation~~total cash consideration, excluding acquisition-related costs, of ~~deferred foreign income~~$17,000. The CES business is a leading provider of testing and ~~(ii) a benefit of $8,692 related~~certification, environmental monitoring and decontamination services for clean rooms and other controlled environments to ~~a revaluation of~~ensure safety, regulatory compliance and quality control, and is included in our ~~deferred tax assets and liabilities. During the third quarter ended April 30, 2018, we reduced the mandatory transition tax by $294. See Non-GAAP Financial Measures below.~~Life Sciences segment.

(dollar amounts in thousands except share and per share data or as otherwise noted) 18

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

~~Legal Matter~~

In May 2017, Cantel Medical (UK) Limited and Cantel (UK) Limited filed a lawsuit in the UK High Court of Justice against ARC Medical Design Limited (“ARC”) seeking a judgment of invalidity on two of ARC’s patents and additionally/alternatively a declaration of non-infringement of our AmplifEYE^TM ~~Endoscopic device. ARC filed counterclaims alleging that the AmplifEYE~~^TM ~~device infringed the two patents as well as registered community design marks and unregistered design rights that ARC had in its Endocuff~~^TM ~~and Endocuff Vision~~^TM devices. In February 2018, the trial judge entered a judgment in favor of ARC, and we decided not to appeal the decision. We entered into a settlement agreement with ARC in March 2018 under which we agreed not to make, use, sell or offer to sell the AmplifEYE^TM device in the European Union until ARC’s rights expire, and reimbursed ARC for a portion of their legal costs. During the third quarter of fiscal 2018, we recorded $2,608 of litigation costs associated with this matter.

~~Acquisitions~~

On March 21, 2018, we purchased all of the issued and outstanding stock of Aexis Medical BVBA ("Aexis Medical"). Aexis Medical specializes in advanced software solutions focused on the tracking and monitoring of instrument reprocessing for hospitals and healthcare professionals. The total consideration was $22,158, consisting of $20,308 up-front consideration net of cash acquired, plus contingent consideration ranging from zero to a maximum of $1,850, which is payable upon the achievement of certain purchase order targets through March 21, 2020. Aexis Medical is included in our Endoscopy segment.

On August 23, 2017, we purchased all of the issued and outstanding stock of BHT Group, a leader in the German market in automated endoscope reprocessing and related equipment and services for total consideration (net of cash acquired), excluding acquisition related costs, of $60,787. The BHT Group consists of a portfolio of high-quality automatic endoscope reprocessors, advanced endoscope storage and drying cabinets (products globally distributed by our Company prior to the acquisition under an agreement with BHT Group), washer-disinfectors for central sterile applications, associated technical service and parts as well as flexible endoscope repair services. BHT Group is included in our Endoscopy segment.

Results of Operations

The following tables give information as to the percentages of net sales represented by selected items reflected in our condensed consolidated statements of income.

Three Months Ended April 30, Percentage Change
Statement of Income Data: 2018 2017
Net sales $ 217,268
100.0 % $ 192,113
100.0 % 13.1 %
Cost of sales 112,594
51.8 % 100,665
52.4 % 11.9 %
Gross profit 104,674
48.2 % 91,448
47.6 % 14.5 %

Selling 33,252
15.3 % 30,509
15.9 % 9.0 %
General and administrative 37,784
17.4 % 29,204
15.2 % 29.4 %
Research and development 6,571
3.0 % 4,291
2.2 % 53.1 %
77,607
35.7 % 64,004
33.3 % 21.3 %

Operating income 27,067
12.5 % 27,444
14.3 % (1.4 )%

Interest expense, net 1,498
0.7 % 1,084
0.6 % 38.2 %
Income before income taxes 25,569
11.8 % 26,360
13.7 % (3.0 )%
Income taxes 6,833
3.2 % 8,849
4.6 % (22.8 )%
Net income $ 18,736
8.6 % $ 17,511
9.1 % 7.0 %

~~(dollar amounts in thousands except share and per share data or as otherwise noted) 19~~

~~Cantel Medical Corp. 2018 Third Quarter Form 10-Q~~


	Nine Months Ended April 30,									Percentage Change		Three Months Ended October 31,									Percentage Change
Statement of Income Data:	2018					2017				Percentage Change		2018				2017					Percentage Change
Net sales	$	643,068		100.0	%	$	564,655	100.0	%	13.9	%	$	225,589	100.0	%	$	212,766		100.0	%	6.0	%
Cost of sales	336,500			52.3	%	295,223		52.3	%	14.0	%	120,340		53.3	%	112,107			52.7	%	7.3	%
Gross profit	306,568			47.7	%	269,432		47.7	%	13.8	%	105,249		46.7	%	100,659			47.3	%	4.6	%

Selling	95,774			14.9	%	85,312		15.1	%	12.3	%	33,958		15.1	%	31,600			14.8	%	7.5	%
General and administrative	102,068			15.9	%	87,672		15.5	%	16.4	%	36,535		16.2	%	32,096			15.1	%	13.8	%
Research and development	17,543			2.7	%	13,328		2.4	%	31.6	%	7,078		3.1	%	5,329			2.5	%	32.8	%
Total operating expenses												77,571		34.4	%	69,025			32.4	%	12.4	%
	215,385			33.5	%	186,312		33.0	%	15.6	%

Operating income	91,183			14.2	%	83,120		14.7	%	9.7	%
Income from operations												27,678		12.3	%	31,634			14.9	%	(12.5	)%

Interest expense, net	3,822			0.6	%	3,303		0.6	%	15.7	%	2,026		0.9	%	1,189			0.6	%	70.4	%
Other income	(1,138		)	(0.2	)%	—		—	%	—	%	—		—	%	(1,138		)	(0.5	)%	—	%
Income before income taxes	88,499			13.8	%	79,817		14.1	%	10.9	%	25,652		11.4	%	31,583			14.8	%	(18.8	)%
Income taxes	14,346			2.3	%	25,436		4.5	%	(43.6	)%	6,410		2.9	%	8,654			4.0	%	(25.9	)%
Net income	$	74,153		11.5	%	$	54,381	9.6	%	36.4	%	$	19,242	8.5	%	$	22,929		10.8	%	(16.1	)%

The following table gives information as to the net sales by reportable segment and geography, as well as the related percentage of such net sales to the total net sales.


	Three Months Ended April 30,								Nine Months Ended April 30,								Three Months Ended October 31,
Net Sales by Segment	2018				2017				2018				2017
Endoscopy	$	118,396	54.5	%	$	100,349	52.2	%	$	347,446	54.0	%	$	288,544	51.1	%
Water Purification and Filtration	52,330		24.1	%	47,940		25.0	%	156,828		24.4	%	145,233		25.7	%
Healthcare Disposables	38,522		17.7	%	36,177		18.8	%	114,898		17.9	%	108,256		19.2	%
Net sales by segment																	2018				2017
Medical																	$	127,552	56.5	%	$	112,385	52.8	%
Life Sciences																	53,345		23.6	%	54,770		25.7	%
Dental																	36,628		16.2	%	37,677		17.7	%
Dialysis	8,020		3.7	%	7,647		4.0	%	23,896		3.7	%	22,622		4.0	%	8,064		3.7	%	7,934		3.8	%
Total net sales	$	217,268	100.0	%	$	192,113	100.0	%	$	643,068	100.0	%	$	564,655	100.0	%	$	225,589	100.0	%	$	212,766	100.0	%
Net Sales by Geography
Net sales by geography
United States	$	159,375	73.4	%	$	146,032	76.0	%	$	478,024	74.3	%	$	442,658	78.4	%	$	168,938	74.9	%	$	160,940	75.6	%
International	57,893		26.6	%	46,081		24.0	%	165,044		25.7	%	121,997		21.6	%	56,651		25.1	%	51,826		24.4	%
Total net sales	$	217,268	100.0	%	$	192,113	100.0	%	$	643,068	100.0	%	$	564,655	100.0	%	$	225,589	100.0	%	$	212,766	100.0	%

(dollar amounts in thousands except share and per share data or as otherwise noted) 19

Cantel Medical Corp. 2019 First Quarter Form 10-Q

The following table gives information as to the amount of ~~operating~~ income from operations, as well as ~~operating~~ income from operations as a percentage of net sales, for each of our reportable segments.

Three Months Ended April 30, Nine Months Ended April 30,
Operating Income by Segment 2018 2017 2018 2017
Endoscopy $ 20,515
17.3 % $ 18,514
18.4 % $ 64,662
18.6 % $ 54,853
19.0 %
Water Purification and Filtration 8,454
16.2 % 7,842
16.4 % 26,753
17.1 % 25,167
17.3 %
Healthcare Disposables 7,588
19.7 % 6,392
17.7 % 23,481
20.4 % 20,857
19.3 %
Dialysis 1,778
22.2 % 2,315
30.3 % 5,795
24.3 % 6,275
27.7 %
Operating income by segment 38,335
17.6 % 35,063
18.3 % 120,691
18.8 % 107,152
19.0 %
General corporate expenses 11,268
5.1 % 7,619
4.0 % 29,508
4.6 % 24,032
4.3 %
Income from operations $ 27,067
12.5 % $ 27,444
14.3 % $ 91,183
14.2 % $ 83,120
14.7 %



	Three Months Ended October 31,
Income from operations by segment	2018				2017
Medical	$	25,211	19.8	%	$	19,684	17.5	%
Life Sciences	6,331		11.9	%	10,375		18.9	%
Dental	5,925		16.2	%	8,675		23.0	%
Dialysis	1,384		17.2	%	2,099		26.5	%
Income from operations by segment	38,851		17.2	%	40,833		19.2	%
General corporate expenses	11,173		4.9	%	9,199		4.3	%
Income from operations	$	27,678	12.3	%	$	31,634	14.9	%

Net Sales

Total net sales increased by ~~$25,155~~$12,823 or ~~13.1%~~6.0%, to ~~$217,268~~$225,589 for the three months ended ~~April 30,~~October 31, 2018 from ~~$192,113~~$212,766 for the three months ended ~~April 30,~~October 31, 2017, which consisted of an increase of 4.3% in organic sales, an increase of 2.3% in net sales due to acquisitions and a decrease of 0.6% due to foreign currency translation. International net sales increased by $4,825 or 9.3%, to $56,651 for the three months ended October 31, 2018 from $51,826 for the three months ended October 31, 2017. The ~~13.1%~~9.3% increase in international net sales consists of 8.1% organic sales growth, a 3.7% increase due to acquisitions, and a decrease of 2.5% due to foreign currency translation.

Medical. Net sales increased by $15,167 or 13.5%, for the three months ended October 31, 2018 compared with the three months ended October 31, 2017, which consisted of 12.8% organic sales growth, a 1.7% increase due to acquisitions and a decrease of 1.0% due to foreign currency translation. The increase in organic net sales was primarily due to capital equipment sales in both the United States and internationally, and recurring revenue growth in all other product lines.

Life Sciences. Net sales decreased by $1,425 or 2.6% for the three months ended October 31, 2018 compared with the three months ended October 31, 2017. The decrease was primarily due to softness in demand for capital equipment, primarily in the medical water business, partially offset by acquisition-related growth. Foreign currency translation decreased net sales by 0.3%, for the three months ended October 31, 2018.

Dental. Net sales decreased by $1,049 or 2.8%, for the three months ended October 31, 2018 compared with the three months ended October 31, 2017. The decrease was primarily driven by a decrease in sales to our distributor network due to inventory adjustments within our channel, partially offset by acquisition-related growth.

Dialysis.Net sales increased by $130 or 1.6%, for the three months ended October 31, 2018 compared with the three months ended October 31, 2017, primarily due to the increase in sales volume for our domestic concentrate.

Gross Profit

Gross profit increased by $4,590 or 4.6%, to $105,249 for the three months ended October 31, 2018 from $100,659 for the three months ended October 31, 2017. Gross profit as a percentage of net sales for the three months ended ~~April 30,~~October 31, 2018 ~~includes an~~and 2017 was 46.7% and 47.3%, respectively. The decrease in gross profit as a percentages of net sales for the three months ended October 31, 2018 was primarily due to the reclassification of certain compensation and benefit-related costs that had previously been recorded in operating expenses into cost of sales, partially offset by higher gross margins from recent acquisitions and higher material costs. The reclassification negatively impacted gross profit as a percentage of net sales by approximately 0.3% for the three months ended October 31, 2018. Excluding the impact of acquisition-related and restructuring-related items, gross profit as a percentage of net sales for the three months ended October 31, 2018 and 2017 was 46.8% and 48.0%, respectively.

Operating Expenses

Operating expenses as a percentage of net sales for the three months ended October 31, 2018 and 2017 was 34.4% and 32.4%, respectively. As stated above, there was a reclassification of certain salary and benefit related costs that had previously been recorded in operating expenses into cost of sales, which positively impacted operating expenses as a percentage of net sales by approximately 0.3% for the three months ended October 31, 2018.

(dollar amounts in thousands except share and per share data or as otherwise noted) 20

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

increase of 7.6% in organic sales, an increase of 4.0% in net sales due to acquisitions and an increase of 1.5% due to foreign currency translation. International net sales increased by $11,812 or 25.6%, to $57,893 for the three months ended April 30, 2018 from $46,081 for the three months ended April 30, 2017. The 25.6% increase international net sales consists of a 15.7% increase due to acquisitions, 3.6% organic sales growth and an increase of 6.4% due to foreign currency translation.

Total net sales increased by $78,413 or 13.9%, to $643,068 for the nine months ended April 30, 2018 from $564,655 for the nine months ended April 30, 2017. The 13.9% increase in net sales for the nine months ended April 30, 2018 includes an increase of 8.8% in organic sales, an increase of 4.1% in net sales due to acquisitions and an increase of 1.0% due to foreign currency translation. International net sales increased by $43,047 or 35.3%, to $165,044 for the nine months ended April 30, 2018 from $121,997 for the nine months ended April 30, 2017. The 35.3% increase in international net sales consists of a 18.7% increase due to acquisitions, 11.9% organic sales growth and an increase of 4.7% due to foreign currency translation.

~~Endoscopy.~~ Net sales of endoscopy products and services increased by $18,047 or 18.0%, for the three months ended April 30, 2018 compared with the three months ended April 30, 2017, which consisted of 8.1% organic sales growth, a 7.2% increase due to acquisitions and an increase of 2.7% due to foreign currency translation. Net sales increased by $58,902 or 20.4%, for the nine months ended April 30, 2018 compared with the nine months ended April 30, 2017, which consisted of 10.8% organic sales growth, a 7.9% increase due to acquisitions and an increase of 1.7% due to foreign currency translation. The increases in organic net sales for the three month and nine month periods were primarily due to volume increases in the United States and internationally for endoscopy procedure products, including storage cabinets and mobile medical carts, disinfectants and service due to the increased installed base of our endoscope reprocessing equipment.

~~Water Purification and Filtration.~~ Net sales of water purification and filtration products and services increased by $4,390 or 9.2%, for the three months ended April 30, 2018 compared with the three months ended April 30, 2017, and by $11,595 or 8.0% for the nine months ended April 30, 2018 compared with the nine months ended April 30, 2017. The increases were primarily due to increased demand for our water purification equipment and increased sales of our chemistries products. Foreign currency translation increased net sales by 0.3% and 0.4%, for the three month and nine month periods ended April 30, 2018, respectively.

~~Healthcare Disposables.~~ Net sales of healthcare disposables products increased by $2,345 or 6.5%, for the three months ended April 30, 2018 compared with the three months ended April 30, 2017, and by $6,642 or 6.1%, for the nine months ended April 30, 2018 compared with the nine months ended April 30, 2017. The increases in net sales were primarily driven by our higher margin products such as sterility assurance and waterline disinfection products, as well as our branded products, and to a lesser extent by acquisition-related growth.

~~Dialysis.~~Net sales of dialysis products and services increased by $373 or 4.9%, for the three months ended April 30, 2018 compared with the three months ended April 30, 2017, and by $1,274 or 5.6%, for the nine months ended April 30, 2018 compared with the nine months ended April 30, 2017. The increases were primarily due to the increase in sales volume for our domestic concentrate.

~~Gross Profit~~

Gross profit increased by $13,226 or 14.5%, to $104,674 for the three months ended April 30, 2018 from $91,448 for the three months ended April 30, 2017, and by $37,136 or 13.8%, to $306,568 for the nine months ended April 30, 2018 from $269,432 for the nine months ended April 30, 2017. Gross profit as a percentage of net sales for the three months ended April 30, 2018 and 2017 was 48.2% and 47.6%, respectively, and for the nine months ended April 30, 2018 and 2017 remained flat at 47.7%. Excluding the impact of acquisition-related and restructuring-related items, gross profit as a percentage of net sales for the three months ended April 30, 2018 and 2017 was 48.2% and 47.8%, respectively, and for the nine months ended April 30, 2018 and 2017 was 48.0% and 47.8%, respectively.

The increases in gross profit as a percentages of net sales for the three and nine months ended April 30, 2018 were primarily due to increased productivity and operational efficiencies, partially offset by the reclassification of certain salary and benefit related costs that had previously been recorded in operating expenses into costs of goods sold. The reclassification negatively impacted gross profit as a percentage of net sales by approximately 0.7% in each of the three month and nine month periods ended April 30, 2017.

~~Operating Expenses~~

Operating expenses as a percentage of net sales for the three months ended April 30, 2018 and 2017 was 35.7% and 33.3%, respectively, and for the nine months ended April 30, 2018 and 2017 was 33.5% and 33.0%, respectively. As stated above, there was a reclassification of certain salary and benefit related costs that had previously been recorded in operating expenses into

~~(dollar amounts in thousands except share and per share data or as otherwise noted) 21~~

~~Cantel Medical Corp. 2018 Third Quarter Form 10-Q~~

~~costs of good sold, which positively impacted operating expenses as a percentage of net sales by approximately 0.7% in each of the three month and nine month periods ended April 30, 2017.~~

Selling expenses increased by ~~$2,743~~$2,358 or ~~9.0%~~7.5%, to ~~$33,252~~$33,958 for the three months ended ~~April 30,~~October 31, 2018 from ~~$30,509~~$31,600 for the three months ended ~~April 30, 2017, and by $10,462 or 12.3%, to $95,774 for the nine months ended April 30, 2018 from $85,312 for the nine months ended April 30,~~October 31, 2017. ~~Selling expenses increased~~The increase was primarily due to higher sales incentive compensation-related costs primarily in our Endoscopy segment, additional sales and marketing initiatives to expand into new markets (including international markets) and the inclusion of selling and marketing expenses of our recent ~~acquisitions.~~acquisitions, and to a lesser extent higher compensation-related costs. Selling expenses as a percentage of net sales were ~~15.3%~~15.1% and ~~15.9%~~14.8% for the three months ended ~~April 30, 2018 and 2017, respectively, and were 14.9% and 15.1% for the nine months ended April 30,~~October 31, 2018 and 2017, respectively.

General and administrative expenses increased by ~~$8,580~~$4,439 or ~~29.4%~~13.8%, to ~~$37,784~~$36,535 for the three months ended ~~April 30,~~October 31, 2018 from ~~$29,204~~$32,096 for the three months ended ~~April 30, 2017, and by $14,396 or 16.4%, to $102,068 for the nine months ended April 30, 2018 from $87,672 for the nine months ended April 30,~~October 31, 2017. ~~General and administrative expenses increased~~The increase was primarily due to ~~incremental~~an increase in acquisition-related items (such as transaction and integration-related costs), higher amortization expense as a result of our recent acquisitions, higher restructuring-related expenses, and the addition of internal and external resources ~~to address~~which support various growth initiatives and compliance requirements and higher acquisition-related items such as transaction and integration costs. General and administrative expenses were also negatively impacted by the third quarter 2018 settlement of a patent infringement matter. These cost increases were partially offset by a decrease in costs associated with the retirement of our former Chief Executive Officer.requirements. General and administrative expenses as a percentage of net sales were ~~17.4%~~16.2% and ~~15.2%~~15.1% for the three months ended ~~April 30, 2018 and 2017, respectively, and 15.9% and 15.5% for the nine months ended April 30,~~October 31, 2018 and 2017, respectively.

Research and development expenses (which include continuing engineering costs) increased by ~~$2,280~~$1,749 or ~~53.1%~~32.8%, to ~~$6,571~~$7,078 for the three months ended ~~April 30,~~October 31, 2018 from ~~$4,291~~$5,329 for the three months ended ~~April 30, 2017, and by $4,215 or 31.6%, to $17,543 for the nine months ended April 30, 2018 from $13,328 for the nine months ended April 30,~~October 31, 2017. The ~~increases were~~increase was primarily due to additional product development initiatives primarily in our ~~Endoscopy~~Medical segment and to a lesser extent in our Life Sciences segment. Research and development expenses as a percentage of net sales were ~~3.0%~~3.1% and ~~2.2%~~2.5% for the three months ended ~~April 30, 2018 and 2017, respectively, and 2.7% and 2.4% for the nine months ended April 30,~~October 31, 2018 and 2017, respectively.

~~Operating~~ Income from Operations

~~Endoscopy.~~ Medical.~~The Endoscopy segment’s operating income~~ Income from operations increased by ~~$2,001~~$5,527 or ~~10.8%~~28.1%, for the three months ended ~~April 30,~~October 31, 2018 compared with the three months ended ~~April 30, 2017, and by $9,809 or 17.9%, for the nine months ended April 30, 2018 compared with the nine months ended April 30,~~October 31, 2017. The ~~increases were~~increase was primarily due to increased sales volume in the United States and internationally for ~~our endoscopy products and services,~~capital equipment, as further explained above. This was partially offset by increases in acquisition-related and ~~restructuring-related costs, litigation matters, sales commission expense, and other~~ compensation-related costs due to increased headcount. The settlement of a patent infringement matter affected operating income as a percentage of sales by approximately 200 basis points for the three months ended April 30, 2018.and inflationary pressures on gross profit.

~~Water Purification and Filtration.~~ Life Sciences.~~The Water Purification and Filtration segment’s operating income increased~~ Income from operations decreased by ~~$612~~$4,044 or ~~7.8%~~39.0%, for the three months ended ~~April 30,~~October 31, 2018 compared with the three months ended ~~April 30, 2017, and by $1,586 or 6.3%, for the nine months ended April 30, 2018 compared with the nine months ended April 30,~~October 31, 2017. The ~~increases were~~decrease was primarily due to ~~due to higher~~lower net sales, ~~partially offset by compensation-related~~restructuring-related costs (including the accelerated amortization of certain intangible assets) and an increase in research and development ~~costs and higher sales commission expenses.~~costs.

~~Healthcare Disposables.~~ Dental.~~The Healthcare Disposables segment’s operating income increased~~ Income from operations decreased by ~~$1,196~~$2,750 or ~~18.7%~~31.7%, for the three months ended ~~April 30,~~October 31, 2018 compared with the three months ended ~~April 30, 2017, and by $2,624 or 12.6%, for the nine months ended April 30, 2018 compared with the nine months ended April 30,~~October 31, 2017. The ~~increases were~~decrease was primarily due to ~~higher~~lower net sales ~~(primarily acquisition-related)~~ and ~~improved~~reduced gross ~~margins resulting~~profit (resulting from ~~increased~~decreased productivity and ~~favorable mix, mostly offset by inventory adjustments, increased compensation-related costs and increased research and development.~~inflationary pressures).

Dialysis.~~The Dialysis segment’s operating income~~ Income from operations decreased by ~~$537~~$715 or ~~23.2%~~34.1%, for the three months ended ~~April 30,~~October 31, 2018 compared with the three months ended ~~April 30, 2017, and by $480 or 7.6%, for the nine months ended April 30, 2018 compared with the nine months ended April 30,~~October 31, 2017. The ~~decreases were~~decrease was primarily due to the shift to lower margin products, partially offset by higher net sales.

~~(dollar amounts in thousands except share and per share data or as otherwise noted) 22~~

~~Cantel Medical Corp. 2018 Third Quarter Form 10-Q~~

General Corporate Expenses

General corporate expenses relate to unallocated corporate costs primarily related to executive management personnel as well as costs associated with certain facets of our acquisition program and being a publicly traded company. Such expenses increased by ~~$3,649~~$1,974 or ~~47.9%~~21.5%, for the three months ended ~~April 30,~~October 31, 2018 from the three months ended ~~April 30, 2017, and by $5,476 or 22.8%, for the nine months ended April 30, 2018 from the nine months ended April 30,~~October 31, 2017. ~~These increases were~~The increase was primarily due to acquisition-related charges and the addition of internal and external resources ~~to address~~which support various growth initiatives and compliance ~~requirements and restructuring-related charges, partially offset by a decrease in costs associated with the retirement of our former Chief Executive Officer.~~requirements.

Interest Expense, Net

Interest expense, net increased by ~~$414~~$837 or ~~38.2%~~70.4%, to ~~$1,498~~$2,026 for the three months ended ~~April 30,~~October 31, 2018 from ~~$1,084~~$1,189 for the three months ended ~~April 30, 2017, and by $519 or 15.7%, to $3,822 for the nine months ended April 30, 2018 from $3,303 for the nine months ended April 30,~~October 31, 2017. ~~These increases~~This increase resulted from an increase in the average outstanding borrowings due to the funding of ~~acquisitions.~~acquisitions and to a lesser extent higher variable interest rates.

Other Income

Other income of $1,138 for the ~~nine~~three months ended ~~April 30, 2018~~October 31, 2017 represents the favorable resolution of the contingent liability associated with the Jet Prep acquisition.

(dollar amounts in thousands except share and per share data or as otherwise noted) 21

Cantel Medical Corp. 2019 First Quarter Form 10-Q

Income Taxes

The consolidated effective tax rate decreased by ~~6.9%~~2.4% to ~~26.7%~~25.0% for the three months ended ~~April 30,~~October 31, 2018 from ~~33.6%~~27.4% for the three months ended ~~April 30, 2017, and decreased by 15.7% to 16.2% for the nine months ended April 30, 2018 from 31.9% for the nine months ended April 30,~~October 31, 2017. The ~~decreases for both periods were~~decrease was primarily attributed to the ~~recording~~change in the federal statutory rate resulting from the 2017 Tax Act, partially offset by foreign and state income taxes, the loss of the ~~discrete net tax benefits associated with the estimated impact of the revaluation of our U.S. net deferred tax liabilities~~Domestic Production Allowance Deduction as a result of the 2017 Tax Act and the ~~revaluation~~reduction of the ~~prior reported~~ excess tax ~~benefits as a result of the change in the U.S. federal statutory rate applicable to~~benefit on stock compensation.

As a result of the 2017 Tax Act, we revised our estimated annual effective rate to reflect the change in the U.S. federal statutory rate by computing a tentative tax under both rates, and then prorating the tentative tax based on the number of days with and without the rate change to arrive at a blended tax rate of 26.9%. This blended rate was applied for fiscal 2018 and the new U.S. federal statutory rate of 21% will apply to fiscal 2019 and beyond.

Non-GAAP Financial Measures

In evaluating our operating performance, we supplement the reporting of our financial information determined under generally accepted accounting principles in the United States (“GAAP”) with certain non-GAAP financial measures including (i) non-GAAP net income, (ii) non-GAAP earnings per diluted share (“EPS”), (iii) earnings before interest, taxes, depreciation, amortization, loss on disposal of fixed assets, and stock-based compensation expense (“EBITDAS”), (iv) adjusted EBITDAS, (v) net debt and (vi) organic sales. These non-GAAP financial measures are indicators of ~~the Company's~~our performance that are not required by, or presented in accordance with, GAAP. They are presented with the intent of providing greater transparency to financial information used by us in our financial analysis and operational decision-making. We believe that these non-GAAP measures provide meaningful information to assist investors, stockholders and other readers of our consolidated financial statements in making comparisons to our historical operating results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.

To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of our past and future performance and are therefore excluded to allow investors to better understand underlying operating trends. The following are examples of the types of adjustments that are excluded: (i) amortization of purchased intangible ~~assets;~~assets, (ii) acquisition-related ~~items;~~items, (iii) business optimization and restructuring-related ~~charges;~~charges, (iv) ~~net~~certain significant and discrete tax ~~benefits associated with the estimated impact of the revaluation of our U.S. net deferred tax liabilities as a result of U.S. tax reform;~~matters and (v) ~~excess tax benefits applicable to stock compensation and (vi)~~ other significant items management deems irregular or non-operating in nature.

~~(dollar amounts in thousands except share and per share data or as otherwise noted) 23~~

~~Cantel Medical Corp. 2018 Third Quarter Form 10-Q~~

Amortization expense of purchased intangible assets is a non-cash expense related to intangibles that were primarily the result of business acquisitions. Our history of acquiring businesses has resulted in significant increases in amortization of intangible assets that reduce ~~the Company’s~~our net income. The removal of amortization from our overall operating performance helps in assessing our cash generated from operations including our return on invested capital, which we believe is an important analysis for measuring our ability to generate cash and invest in our continued growth.

Acquisition-related items consist of (i) fair value adjustments to contingent consideration and other contingent liabilities resulting from acquisitions, (ii) due diligence, integration, legal fees and other transaction costs associated with our acquisition program and (iii) acquisition accounting charges for the amortization of the initial fair value adjustments of acquired inventory and deferred revenue. The adjustments of contingent consideration and other contingent liabilities are periodic adjustments to record such amounts at fair value at each balance sheet date. Given the subjective nature of the assumptions used in the determination of fair value calculations, fair value adjustments may potentially cause significant earnings volatility that are not representative of our operating results. Similarly, due diligence, integration, legal and other acquisition costs associated with our acquisition program, including ~~acquisition~~ accounting charges relating to recording acquired inventory and deferred revenue at fair market value, can be significant and also adversely impact our effective tax rate as certain costs are often not tax-deductible. Since these acquisition-related items are irregular and often mask underlying operating performance, we exclude these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to past operating performance.

The 2017 Tax Act significantly revised U.S. tax law by, among other provisions, (a) lowering the applicable U.S. federal statutory income tax rate from 35% to 21%, (b) creating a partial territorial tax system that includes imposing a mandatory one-time transition tax on previously deferred foreign earnings, (c) creating provisions regarding the (1) Global Intangible Low Tax Income, (2) the Foreign Derived Intangible Income deduction, and (3) the Base Erosion Anti-Abuse Tax and (d) eliminating or reducing certain income tax deductions, such as interest expense, executive compensation expenses and certain employee expenses. During the second quarter ended January 31, 2018, we recorded a net benefit as a provisional estimate of the net accounting impact of the 2017 Tax Act in accordance with SAB 118. The net benefit is comprised of the following: (i) an unfavorable impact related to the mandatory transition tax for deemed repatriation of deferred foreign income and (ii) a favorable benefit related to a revaluation of the Company’s deferred tax assets and liabilities. During the third quarter ended April 30, 2018, we recorded an adjustment to the mandatory transition tax. Since these net favorable tax benefits are largely unrelated to our results and unrepresentative of our normal effective tax rate, we excluded their impact on net income and diluted EPS to arrive at our non-GAAP financial measures.

Excess tax benefits resulting from stock compensation are recorded as a reduction of income tax expense. The magnitude of the impact of excess tax benefits generated in the future, which may be favorable or unfavorable, are dependent upon our future grants of equity awards, our future share price on the date awards vest in relation to the fair value of awards on grant date and the exercise behavior of our stock award holders. Since these tax benefits are largely unrelated to our results and unrepresentative of our normal effective tax rate, we excluded their impact on net income and diluted EPS to arrive at our non-GAAP financial measures. For the three months ended January 31, 2018 and as a result of the 2017 Tax Act, we revised our estimated annual effective rate to reflect the change in the U.S. federal statutory rate applicable to stock compensation. The reduction in the federal rate applicable to the gains and corollary deferred tax asset resulted in a decrease in the excess tax benefit reported for

During the three months ended October 31, ~~2017.~~

~~During the third quarter of fiscal~~ 2018, we ~~settled a patent infringement matter and also~~ recorded ~~an adjustment~~specific discrete tax items associated with our international operations that were unrelated to ~~another litigation matter in our consolidated financial statements. In~~ fiscal ~~2016, we announced the retirement plans~~2019. As these items are unrepresentative of our former Chief Executive Officer and recorded the majority of the costs associated with his retirement in our consolidated financial statements. Since these costs are irregular and mask our underlying operating performance,normal effective tax rate, we ~~made an adjustment to our~~excluded their impact on net income and diluted EPS to ~~exclude such costs to~~ arrive at our non-GAAP financial measures.

~~Three Months Ended April 30, 2018~~

We made adjustments to net income and diluted EPS to exclude (i) amortization expense of purchased intangible assets, (ii) acquisition-related items, (iii) other business optimization and restructuring-related charges, (iv) litigation matters and (v) the reduction of a repatriation tax related to the 2017 Tax Act to arrive at our non-GAAP financial measures, non-GAAP net income and non-GAAP diluted EPS.

(dollar amounts in thousands except share and per share data or as otherwise noted) 2422

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

~~Three Months Ended April 30,~~In November 2017,

We the Israeli Government notified us that they would forgive any future amounts due under a contingent obligation payable from a previous acquisition. As a result of this formal notification, we reduced the $1,138 contingent obligation payable to zero during the three months ended October 31, 2017, resulting in a gain through other income. Since this gain was irregular, we made ~~adjustments~~an adjustment to our net income and diluted EPS to exclude ~~(i) amortization expense of purchased intangible assets, (ii) acquisition-related items and (iii) other business optimization and restructuring-related charges~~this gain to arrive at our non-GAAP financial ~~measures, non-GAAP net income and non-GAAP diluted EPS.~~measures.

~~The reconciliations of net income and diluted EPS to non-GAAP net income and non-GAAP diluted EPS were calculated as follows:~~

Three Months Ended April 30,
2018 2017
Net income/Diluted EPS, as reported $ 18,736
$ 0.45
$ 17,511
$ 0.42
Intangible amortization, net of tax⁽¹⁾
3,468
0.08
2,852
0.07
Acquisition-related items, net of tax⁽²⁾
651
0.02
465
0.01
Restructuring-related charges, net of tax⁽³⁾
991
0.02
549
0.01
Litigation matters⁽¹⁾
1,637
0.04
—
—
Tax legislative changes⁽⁴⁾
(554 ) (0.01 ) —
—
Non-GAAP net income/Non-GAAP diluted EPS $ 24,929
$ 0.60
$ 21,377
$ 0.51


~~(1)~~	~~Amounts were recorded in general and administrative expenses.~~


~~(2)~~	For the three months ended April 30, 2018, pre-tax acquisition-related items of $953 were recorded in general and administrative expenses. For the three months ended April 30, 2017, pre-tax acquisition-related items of $330 were recorded in cost of sales and $390 were recorded in general and administrative expenses.


~~(3)~~	For the three months ended April 30, 2018, pre-tax restructuring-related items of $17 were recorded in cost of sales and $1,466 were recorded in general and administrative expenses. For the three months ended April 30, 2017, pre-tax restructuring-related items of $879 were recorded in general and administrative expenses.


~~(4)~~	~~Amounts were recorded in income taxes.~~

~~Nine~~Three Months Ended ~~April 30,~~October 31, 2018

We made adjustments to net income and diluted EPS to exclude (i) amortization expense of purchased intangible assets, (ii) acquisition-related items, (iii) other business optimization and restructuring-related charges, (iv) excess tax benefits applicable to stock compensation, (v) ~~net~~ tax ~~benefits associated with the estimated impact of the revaluation of our U.S. net deferred tax liabilities as a result of the 2017 Tax Act,~~matters and (vi) litigation matters ~~and (vii) the resolution of the contingent liability associated with a previous acquisition~~ to arrive at our non-GAAP financial measures, non-GAAP net income and non-GAAP diluted EPS.

~~Nine~~Three Months Ended ~~April 30,~~October 31, 2017

We made adjustments to net income and diluted EPS to exclude (i) amortization expense of purchased intangible assets, (ii) acquisition-related items, (iii) other business optimization and restructuring-related charges, (iv) excess tax benefits applicable to stock compensation and (v) ~~costs~~the resolution of the contingent liability associated with the ~~retirement of our former Chief Executive Officer~~Jet Prep acquisition to arrive at our non-GAAP financial measures, non-GAAP net income and non-GAAP diluted EPS.

~~(dollar amounts in thousands except share and per share data or as otherwise noted) 25~~

~~Cantel Medical Corp. 2018 Third Quarter Form 10-Q~~

The reconciliations of net income and diluted EPS to non-GAAP net income and non-GAAP diluted EPS were calculated as follows:


	Nine Months Ended April 30,												Three Months Ended October 31,
	2018						2017						2018						2017
Net income/Diluted EPS, as reported	$	74,153		$	1.77		$	54,381		$	1.30		$	19,242		$	0.46		$	22,929		$	0.55
Intangible amortization, net of tax⁽¹⁾	9,844			0.24			8,438			0.20			4,626			0.11			2,869			0.07
Acquisition-related items, net of tax⁽²⁾	2,307			0.06			1,233			0.03			1,349			0.03			1,081			0.03
Restructuring-related charges, net of tax⁽³⁾	2,844			0.07			1,191			0.03			641			0.02			586			0.01
Excess tax benefit⁽⁴⁾	(2,012		)	(0.05		)	(2,241		)	(0.05		)	(997		)	(0.02		)	(2,286		)	(0.05		)
Tax legislative changes⁽⁴⁾	(8,952		)	(0.22		)	—			—
Tax matters⁽⁴⁾													896			0.02			—			—
Litigation matters⁽¹⁾	1,637			0.04			—			—			134			—			—			—
Resolution of contingent liability⁽⁵⁾	(1,138		)	(0.03		)	—			—			—			—			(1,138		)	(0.03		)
CEO retirement costs, net of tax⁽¹⁾	—			—			1,249			0.03
Non-GAAP net income/Non-GAAP diluted EPS	$	78,683		$	1.88		$	64,251		$	1.54		$	25,891		$	0.62		$	24,041		$	0.57


(1)	Amounts were recorded in general and administrative expenses.

(2)

For the ~~nine~~three months ended ~~April 30,~~October 31, 2018, pre-tax acquisition-related items of $217 were recorded in net sales, $54 were recorded in cost of sales and $1,555 were recorded in general and administrative expenses. For the three months ended October 31, 2017, pre-tax acquisition-related items of $893 were recorded in cost of sales and ~~$2,409 were recorded in general and administrative expenses. For the nine months ended April 30, 2017, pre-tax acquisition-related items of $500 were recorded in cost of sales and $1,295~~$916 were recorded in general and administrative expenses.

(3)

For the ~~nine~~three months ended ~~April 30,~~October 31, 2018, pre-tax restructuring-related items of ~~$1,164~~$166 were recorded in cost of sales and ~~$2,656~~$680 were recorded in general and administrative expenses. For the ~~nine~~three months ended ~~April 30,~~October 31, 2017, pre-tax restructuring-related items of ~~$1,735~~$505 were recorded in cost of sales and $443 were recorded in general and administrative expenses.


(4)	Amounts were recorded in income taxes.


(5)	Amounts were recorded in other income.

We believe EBITDAS is an important valuation measurement for management and investors given the increasing effect that non-cash charges, such as stock-based compensation, amortization related to acquisitions and depreciation of capital equipment have on net income. In particular, acquisitions have historically resulted in significant increases in amortization of purchased intangible assets that reduce net income. Additionally, we regard EBITDAS as a useful measure of operating performance and cash flow before the effect of interest expense and is a complement to ~~operating~~ income from operations, net income and other GAAP financial performance measures.

We define adjusted EBITDAS as EBITDAS excluding the same non-GAAP adjustments to net income discussed ~~previously in this document.~~above. We use adjusted EBITDAS when evaluating operating performance because we believe the exclusion of such adjustments, of which a significant portion are non-cash items, is necessary to provide the most accurate measure of on-going core operating results and to evaluate comparative results period over period.

(dollar amounts in thousands except share and per share data or as otherwise noted) 2623

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

The reconciliations of net income to EBITDAS and adjusted EBITDAS were calculated as follows:


	Three Months Ended April 30,				Nine Months Ended April 30,					Three Months Ended October 31,
	2018		2017		2018			2017		2018		2017
Net income, as reported	$	18,736	$	17,511	$	74,153		$	54,381	$	19,242	$	22,929
Interest expense, net	1,498		1,084		3,822			3,303		2,026		1,189
Income taxes	6,833		8,849		14,346			25,436		6,410		8,654
Depreciation	4,626		3,774		12,816			10,922		4,691		4,036
Amortization	4,480		3,964		12,892			11,930		6,041		4,048
Loss on disposal of fixed assets	187		87		521			489		1,053		69
Stock-based compensation expense	2,443		1,945		7,033			6,983		2,576		1,851
EBITDAS	38,803		37,214		125,583			113,444		42,039		42,776
Acquisition-related items	953		720		3,302			1,795		1,827		1,809
Restructuring-related charges⁽¹⁾	1,468		879		3,721			1,735		742		948
Litigation matters	2,345		—		2,345			—		163		—
Resolution of contingent liability	—		—		(1,138		)	—		—		(1,138		)
CEO retirement costs⁽²⁾	—		—		—			1,413
Adjusted EBITDAS	$	43,569	$	38,813	$	133,813		$	118,387	$	44,771	$	44,395


(1)	Excludes stock-based compensation expense.


~~(2)~~	For comparative purposes, we have revised the amounts associated with CEO retirement costs for the nine months ended April 30, 2017 to exclude stock-based compensation expense which was reported in "Stock-based compensation expense" above.

We define net debt as long-term debt less cash and cash equivalents. Each of the components of net debt appears on our consolidated balance sheets. We believe that the presentation of net debt provides useful information to investors because we review net debt as part of our management of our overall liquidity, financial flexibility, capital structure and leverage.


	April 30, 2018			July 31, 2017			October 31, 2018			July 31, 2018
Long-term debt	$	169,000		$	126,000
Long-term debt (excluding debt issuance costs)							$	197,500		$	200,000
Less cash and cash equivalents	(51,916		)	(36,584		)	(64,030		)	(94,097		)
Net debt	$	117,084		$	89,416		$	133,470		$	105,903

We define organic sales as net sales less (i) the impact of foreign currency translation, (ii) net sales related to acquired businesses during the first twelve months of ownership and (iii) divestitures during the periods being compared. We believe that reporting organic sales provides useful information to investors by helping identify underlying growth trends in our business and facilitating easier comparisons of our revenue performance with prior periods. We exclude the effect of foreign currency translation from organic sales because foreign currency translation is not under management’s control, is subject to volatility and can obscure underlying business trends. We exclude the effect of acquisitions and divestitures because the nature, size, and number of acquisitions and divestitures can vary dramatically from period to period and can obscure underlying business trends and make comparisons of financial performance difficult. The reconciliation of net sales to organic sales can be found elsewhere in this MD&A in “Net Sales.”

Liquidity and Capital Resources

We assess our liquidity in terms of our ability to generate cash to fund operating, investing and financing activities. Significant factors affecting the management of liquidity are cash flows generated from operating activities, capital expenditures, acquisitions of businesses and cash dividends. Cash provided by operating activities continues to be a primary source of funds. As necessary, we supplement operating cash flow with borrowings from our revolving credit facility to fund our acquisitions and related business activities.

Cash Flows

Net Cash Provided by Operating Activities. Net cash provided by operating activities increased by ~~$16,619~~$2,197 or ~~22.6%~~7.3%, to ~~$90,003~~$32,269 for the ~~nine~~three months ended ~~April 30,~~October 31, 2018 from ~~$73,384~~$30,072 for the ~~nine~~three months ended ~~April 30,~~October 31, 2017, primarily due to the timing of accounts payable and annual insurance premiums, partially offset by decreased cash collections of outstanding accounts receivable and the decrease in net income.

(dollar amounts in thousands except share and per share data or as otherwise noted) 2724

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

increase in net income, increased cash collections associated with outstanding accounts receivables and the timing of accounts payable, partially offset by the timing of income tax payments, the increase in inventories to support product demand and timing of our annual insurance premium payments.

Net Cash Used in Investing Activities. Net cash used in investing activities ~~increased~~decreased by ~~$17,991~~$11,003 or ~~19.9%~~16.5%, to ~~$108,367~~$55,834 for the ~~nine~~three months ended ~~April 30,~~October 31, 2018 from ~~$90,376~~$66,837 for the ~~nine~~three months ended ~~April 30,~~October 31, 2017, primarily due to ~~an increase~~a decrease in cash paid for acquisitions, ~~and to a lesser extent, an~~partially offset by increase in capital ~~expenditures.~~expenditures (primarily related to the purchase of a new facility and our enterprise resource planning project).

Net Cash (Used in) Provided by Financing Activities. Net cash (used in) provided by financing activities increased by ~~$13,546~~$42,966 or ~~68.8%~~118.8%, to ~~$33,238~~$6,788 for the ~~nine~~three months ended ~~April 30,~~October 31, 2018 from ~~$19,692~~$36,178 for the ~~nine~~three months ended ~~April 30,~~October 31, 2017, primarily due to a ~~net increase~~reduction in ~~revolver borrowings to fund acquisitions.~~

~~Dividends~~

~~On November 1, 2017, our Board of Directors approved a 21% increase in~~debt repayments due the semi-annual cash dividend to approximately $0.09 per share of outstanding common stock, which was paid on January 31, 2018 to shareholders of record at the close of business on January 17, 2018. Future declarations of dividends and the establishment of future record and payment dates are subject to the final determinationnature of our ~~Board of Directors.~~term loan, which provides for fixed quarterly principal payments.

Debt

~~On April 30,~~At October 31, 2018, we had ~~$169,000~~$197,500 of outstanding term loan borrowings under our ~~Third~~Fourth Amended and Restated Credit Agreement (the ~~“2014~~“2018 Credit Agreement”).

For further information regarding the ~~2014~~2018 Credit Agreement, including a description of affirmative and negative covenants, see Note 910 to our condensed consolidated financial statements in Part I, Item 1 of this report.

Financing Needs

~~On April 30,~~At October 31, 2018, our long-term debt (excluding debt issuance costs) of ~~$169,000,~~$197,500, net of our cash and cash equivalents of ~~$51,916,~~$64,030, was ~~$117,084.~~$133,470. Stockholders' equity as of that date was ~~$601,306.~~$622,360.

Our operating segments generate significant cash from operations. At ~~April 30,~~October 31, 2018, we had a cash balance of ~~$51,916,~~$64,030, of which ~~$27,358~~$35,087 was held by foreign subsidiaries. Our foreign cash is needed by our foreign subsidiaries for working capital purposes as well as for current international growth initiatives. Accordingly, our foreign unremitted earnings are considered indefinitely reinvested and unavailable for repatriation.

We believe that our current cash position, anticipated cash flows from operations and the funds available under our ~~2014~~2018 Credit Agreement will be sufficient to satisfy our worldwide cash operating requirements for the foreseeable future based upon our existing operations, particularly given that we historically have not needed to borrow for working capital purposes. At ~~June 1,~~November 30, 2018, approximately ~~$86,000~~$399,729 was available under our ~~2014~~2018 Credit Agreement.

Critical Accounting Policies

There were no changes to our critical accounting policies from those disclosed in our ~~2017~~2018 Annual Report on Form 10-K.

Forward Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” as that term is defined under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates, or forecasts about our businesses, the industries in which we operate, and the current beliefs and assumptions of management; they do not relate strictly to historical or current facts. Without limiting the foregoing, words or phrases such as “expect,” “anticipate,” “goal,~~” “will continue,~~” “project,” “intend,” “plan,” “believe,” “seek,” “may,” “could” and variations of such words and similar expressions generally identify forward-looking statements. In addition, any statements that refer to predictions or projections of our future financial performance, anticipated growth and trends in our businesses, and other characterizations of future events or circumstances are forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions about future events, activities or developments and are subject to numerous risks, uncertainties, and assumptions that are difficult to predict. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made.

~~(dollar amounts in thousands except share and per share data or as otherwise noted) 28~~

~~Cantel Medical Corp. 2018 Third Quarter Form 10-Q~~

Some of the factors which could cause results to differ from those expressed in any forward-looking statement are set forth under Item 1A of the ~~2017~~2018 Annual Report on Form 10-K, entitled Risk Factors. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

For these statements, we claim the protection of the safe harbor for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

(dollar amounts in thousands except share and per share data or as otherwise noted) 25

Cantel Medical Corp. 2019 First Quarter Form 10-Q

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in the information reported in Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk, in our ~~2017~~2018 Annual Report on Form 10-K.

Item 4. Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the SEC and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this ~~report~~Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer each concluded that the design and operation of these disclosure controls and procedures were effective and designed to ensure that material information relating to the Company, including our consolidated subsidiaries, required to be disclosed in our SEC reports is (i) recorded, processed, summarized and reported within the time periods specified by the SEC and (ii) accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure.

We have evaluated our internal control over financial reporting and determined that no changes occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, except as described below.

On ~~August 23, 2017, we acquired BHT Group, and on~~ March 21, 2018, we acquired Aexis, ~~Medical,~~and on August 1, 2018, we acquired the CES business, as more fully described in Note 3 to the condensed consolidated financial statements. During the initial transition period following the acquisitions, we enhanced our internal control process to ensure that all financial information related to these acquisitions was properly reflected in our condensed consolidated financial statements. We expect all aspects of the ~~BHT Group~~Aexis business ~~will be fully integrated into our existing overall internal control structure by the end of fiscal 2018. We expect all aspects of the Aexis Medical~~and CES business will be fully integrated into our existing overall internal control structure during fiscal 2019.

~~Cantel Medical Corp. 2018 Third Quarter Form 10-Q~~

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

There have been no material changes in our risk factors from those disclosed in Part I, Item 1A to our ~~2017~~2018 Annual Report on Form 10‑K. The risk factors disclosed in Part I, Item 1A to our ~~2017~~2018 Annual Report on Form 10-K, in addition to the other information set forth in this report, could materially affect our business, financial condition, or results of operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table represents information with respect to purchases of common stock made by the Company during the current quarter:

Period
Total number of
shares purchased

Average price
paid per share
Total number of shares purchased as part of publicly announced plans or programs Maximum number of shares that may yet be purchased under the program
February 1 - February 28 529
$ 112.62
—
—
March 1 - March 31 1,211
$ 112.63
—
—
April 1 - April 30 596
$ 113.98
—
—
Total 2,336
$ 112.97
—
—



Period	Total number of shares purchased	Average price paid per share		Total number of shares purchased as part of publicly announced plans or programs	Maximum number of shares that may yet be purchased under the program
August 1 - August 31	793	$	94.40	—	—
September 1 - September 30	59	$	96.39	—	—
October 1 - October 31	47,392	$	88.78	—	—
Total	48,244	$	88.88	—	—

The Company does not currently have a repurchase program. All of the shares purchased during the current quarter represent shares surrendered to the Company to pay employee withholding taxes due upon the vesting of restricted stock.

Cantel Medical Corp. 2019 First Quarter Form 10-Q

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

Item 6. Exhibits



	10.1		Cantel Medical Corp. 2016 Equity Incentive Plan (as amended through October 31, 2018)

	31.1		Certification of Principal Executive Officer.

	31.2		Certification of Principal Financial Officer.

	32		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section ~~1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.~~1350.

	101		The following materials from this report, formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Cash Flows and (v) Notes to Condensed Consolidated Financial Statements.

(dollar amounts in thousands except share and per share data or as otherwise noted) 3027

Cantel Medical Corp. ~~2018 Third~~2019 First Quarter Form 10-Q

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	CANTEL MEDICAL CORP.

Date: ~~June 1,~~November 30, 2018

	By:	/s/ Jorgen B. Hansen
		Jorgen B. Hansen,
		President and Chief Executive Officer
		(Principal Executive Officer)


	By:	/s/ Peter G. Clifford
		Peter G. Clifford,
		Executive Vice President and Chief Financial Officer
		(Principal Financial Officer)


	By:	/s/ Brian R. Capone
		Brian R. Capone
		Senior Vice President and Chief Accounting Officer
		(Principal Accounting Officer)

3128



	Number of Time-based Awards		Number of Performance-based Awards		Number of Market-based Awards		Number of Total Awards		Weighted Average Fair Value
July 31, 2017	196,818		16,235		9,245		222,298		$	66.28
Granted	94,130		18,647		10,465		123,242		$	101.73
Vested⁽¹⁾	(99,009	)	(6,162	)	—		(105,171	)	$	58.98
Forfeited	(6,623	)	(1,743	)	(2,000	)	(10,366	)	$	91.09
April 30, 2018	185,316		26,977		17,710		230,003		$	87.55



	Consolidated Effective Income Tax Rate
	Three Months Ended		Nine Months Ended
April 30, 2017	33.6	%	31.9	%
Difference attributable to:
Deferred tax revaluation	(0.4	)%	(7.0	)%
U.S. federal statutory rate decrease⁽¹⁾	(8.1	)%	(8.1	)%
Foreign operations	(1.3	)%	(0.3	)%
State taxes	3.5	%	1.5	%
Excess tax benefit	—	%	(2.3	)%
Other	(0.6	)%	0.5	%
April 30, 2018	26.7	%	16.2	%



	Three Months Ended April 30,								Nine Months Ended April 30,
Operating Income by Segment	2018				2017				2018				2017
Endoscopy	$	20,515	17.3	%	$	18,514	18.4	%	$	64,662	18.6	%	$	54,853	19.0	%
Water Purification and Filtration	8,454		16.2	%	7,842		16.4	%	26,753		17.1	%	25,167		17.3	%
Healthcare Disposables	7,588		19.7	%	6,392		17.7	%	23,481		20.4	%	20,857		19.3	%
Dialysis	1,778		22.2	%	2,315		30.3	%	5,795		24.3	%	6,275		27.7	%
Operating income by segment	38,335		17.6	%	35,063		18.3	%	120,691		18.8	%	107,152		19.0	%
General corporate expenses	11,268		5.1	%	7,619		4.0	%	29,508		4.6	%	24,032		4.3	%
Income from operations	$	27,067	12.5	%	$	27,444	14.3	%	$	91,183	14.2	%	$	83,120	14.7	%